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ABSTRACT
Carotid artery disease is a prevalent etiologic precursor of ischemic stroke, 
which is a major health hazard and the second most common cause of death 
in the world. If a patient presents with a symptomatic high-grade (>70%) 
stenosis in the internal carotid artery, the treatment of choice is carotid 
endarterectomy. However, the natural course of radiologically equivalent 
carotid lesions may be clinically quite diverse, and the reason for that is 
unknown. It would be of utmost importance to identify molecular markers 
that predict the symptomatic phenotype of an atherosclerotic carotid plaque 
(CP) and help to diff erentiate vulnerable, rupture-prone lesions from stable 
ones. Th is would permit the expedition of operative treatment of vulnerable 
lesions, or the avoidance of unnecessary surgery and, furthermore, facilitate 
the development of plaque-stabilizing therapies. 
Th e aim of this study was to investigate the morphological and 
molecular markers that associate with stroke-prone CPs. In addition to 
immunohistochemistry, DNA microarrays were utilized to identify molecular 
markers that would diff erentiate symptomatic from asymptomatic CPs.
Th e concept of atherosclerosis as an infl ammatory disease is well 
established, but it turned out that endothelial adhesion molecule expression 
(ICAM-1, VCAM-1, P-selectin, and E-selectin) did not diff er between 
symptomatic and asymptomatic patients. Hence, infl ammation as the sole 
underlying cause leading to the destabilization of a CP seems unlikely. 
Denudation of endothelial cells was associated with symptom-generating 
carotid lesions, which underscores the integrity of the endothelial lining as a 
protection against thromboembolic events. When examining the mechanism 
of decay of endothelial cells, markers of apoptosis (TUNEL, activated caspase 
3) were found to be decreased in the endothelium of symptomatic lesions, 
which argues against the view that apoptosis would be a dominant reason for 
denudation. Furthermore, the direct association of markers of endothelial 
apoptosis with those of cell proliferation (Ki-67) in all plaques suggests 
that ongoing cellular turnover promotes the integrity of the endothelial 
lining. Although there was less immunostaining for markers of apoptosis 
in symptomatic CPs, FasL expression was signifi cantly increased on their 
endothelium. Th is suggests an independent detrimental role for FasL in the 
destabilization of carotid plaques.
DNA microarray analysis revealed prominent induction of specifi c 
genes in symptomatic CPs, including those participating in the iron and 
heme metabolism, namely heme oxygenase-1 (HO-1) and hemoglobin 
scavenger receptor CD163. HO-1 and CD163 proteins were also increased 
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in symptomatic CPs and associated with intraplaque iron deposits, which, 
however, did not correlate with symptom status itself. Th is suggests an 
indirect linkage between intraplaque hemorrhages and CP destabilization 
and implies that a stronger activation response to microhemorrhages 
and free iron may take place in symptomatic CPs. ADFP, the gene for 
adipophilin, was also overexpressed in symptomatic CPs, suggesting a 
role of lipids and foam cell formation in the symptomatic phenotype of 
CPs. Adipophilin expression was markedly increased in ulcerated CPs and 
colocalized with extravasated red blood cells and cholesterol crystals. Th is 
suggest an indirect role of intraplaque hemorrhages in the destabilization 
of CPs, which may fundamentally contribute to the lipid load of an 
atherosclerotic carotid lesion.
Taken together, the denudation of the endothelial lining observed in 
symptomatic CPs may lead to direct thromboembolism and maintain 
harmful local oxidative and infl ammatory processes, predispose to plaque 
microhemorrhages, and contribute to lipid accumulation into the plaque, 
thereby making it vulnerable to rupture. Th e phenotypic characteristics and 
the numerous possible molecular mediators of the destabilization of carotid 
plaques provide potential platforms for future research. 
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INTRODUCTION
An atherosclerotic lesion in the carotid artery is an important cause of 
ischemic stroke, accounting for approximately a third of ischemic brain 
infarctions1,2. A symptomatic carotid lesion presents a remarkable risk for 
recurrent stroke (6-18% during the fi rst year, increasing with the degree 
of stenosis3), and if the patient presents with a symptomatic high-grade 
(>70%) carotid stenosis, endarterectomy is considered the gold standard of 
treatment4. Th e estimated annual risk for stroke with asymptomatic stenosis 
ranges from 2% to 5%5-8, and it has not been fully established whether 
the risk for stroke exceeds the risk of complications involved in surgical 
intervention, which makes the treatment of asymptomatic stenosis far more 
problematic. Th e clinical course of radiologically similar symptomatic and 
asymptomatic carotid stenoses are very diff erent3,4,9,10, and the intrinsic 
properties of plaques are likely to be responsible for their divergent clinical 
behaviors.
Th e evolution of an atherosclerotic plaque is a process where interrelated 
cellular processes (lipid accumulation and oxidation, infl ammatory cell 
infi ltration, smooth muscle cell proliferation, etc.) take place in interaction 
with various infl uences of systemic factors (lipid load, hemostatic changes, 
hemodynamic alterations, infections, etc.) and constant shear stress. Th ere 
has been a lot of research to identify the factors that fuel the vulnerability of an 
atherosclerotic lesion, but the governing mechanisms have not been defi ned. 
Initially, endothelial injury is oft en observed11–13. Blood lipids accumulate 
within the vessel wall, leading to an infl ammatory state, accumulation 
of lipid-laden foam cells, the formation of fatty streaks, and eventual 
thickening of the wall14–17. Th e diseased vessel wall may lead to ischemic 
cerebral symptoms due to plaque rupture and local thrombosis, artery-to-
artery embolus, or gradual occlusion leading to cerebral hypoperfusion. 
Studies that have compared symptomatic and asymptomatic carotid plaques 
histologically have shown that, in symptomatic plaques, plaque rupture or 
ulceration is much more common, the fi brous cap is thinner, infl ammation 
is more common with more abundant infl ammatory cells, like macrophages 
and T cells in the cap, the quantity of extractable lipids is higher, and the 
necrotic core is located closer to the fi brous cap (reviewed by Golledge 
and coworkers18). In vitro studies of coronary plaques have demonstrated 
high levels of matrix metalloproteinases (MMPs) lining the infl ammatory 
infi ltrate in the fi brous cap19, and smooth muscle cell apoptosis has also 
been demonstrated to be more dominant in unstable plaques20. Leukocyte 
recruitment is dependent on the expression of adhesion molecules on the 
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endothelial surface, and increases in correlation with the increasing quantity 
of infl ammatory cells in the fi brous cap21,22. DeGraba and coworkers showed 
ICAM-1 adhesion molecule expression to be increased on the endothelium 
of symptomatic carotid plaques23. Although plaque rupture has clearly been 
associated with symptom generation, postmortem studies have suggested 
that the rupture in itself is oft en asymptomatic, and that symptoms are more 
likely to develop if the rupture-associated thrombus is large24.
Not all patients are eligible for surgical interventions, due to comorbidity 
or advanced age. Hence, the following future challenges should be met: fi rst, 
to fi nd the means to diff erentiate vulnerable, stroke-prone plaques from 
stable ones, and second, to identify the mechanisms of plaque destabilization 
to enable the development of preventive or plaque-targeted stabilizing 
therapies. Th ese issues formed the background to the initiation of the present 
study.
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REVIEW OF THE LITERATURE
CAROTID DISEASE AND STROKE
Stroke – deﬁ nition and classiﬁ cation
Stroke is a clinical syndrome characterized by an acute loss of focal cerebral 
function with symptoms lasting for more than 24 hours or leading to death. 
It is thought to be due to either spontaneous hemorrhage into the brain 
substance or inadequate cerebral blood supply to a part of the brain as a result 
of limited blood fl ow, thrombosis, or embolism associated with diseases of 
the blood vessels, heart, or blood2 (Figure 1). If the symptoms or signs persist 
for less than 24 hours, the condition is called a transient ischemic attack 
(TIA)2. However, it cannot be clinically distinguished whether a relevant 
infarct exists in computed tomography aft er a TIA or not25.
As a clinical syndrome, stroke is highly heterogenous, and its numerous 
etiological factors infl uence the prognosis, the type of treatment required, 
and the preventive strategies. Approximately 80% of all strokes are 
ischemic, 10–15% are due to intracerebral hemorrhages, and the rest are 
due to subarachnoid hemorrhages (<10%) and undetermined pathological 
conditions (Table 1). Moreover, the etiological basis of ischemic strokes is 
heterogeneous: the major causes are atherosclerosis of extra- and intracranial 
arteries (8–50%), cardiogenic embolism (14–30%), and penetrating small 
artery disease (15–30%) (Table 1). Due to this heterogeneity, ischemic 
strokes have been classifi ed into subtypes according to the underlying 
conditions as follows (TOAST subtype classifi cation system): 1) large-artery 
atherosclerosis, 2) cardioembolism, 3) small-artery occlusion (lacune), 4) 
stroke of other determined etiology, and 5) stroke of undetermined etiology26. 
Th is classifi cation is based on clinical features and data collected by tests such 
as brain imaging (CT/MRI), cardiac imaging (echocardiography), duplex 
imaging of extracranial arteries, arteriography, and laboratory assessments 
for prothrombotic states.
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Figure 1 Ischemic stroke caused by an atheromatous plaque in the internal carotid artery. Th e 
atherosclerotic stenosis may give rise to thromboemboli which impair cerebral blood fl ow 
in the area supplied by that artery (left -hand panel). Th e lesion may also hemodynamically 
deteriorate cerebral perfusion by causing gradual occlusion of the carotid bifurcation 
or ICA. Th is results in a cerebral infarction that can be visualized by e.g. computed 
tomography of the brain (right-hand panel).
Table 1. Distribution of pathological types of stroke, and ischemic stroke subtypes.
PATHOLOGICAL TYPES OF STROKE FREQUENCY REFERENCES
Ischemic stroke 72–86% 1, 2, 3
Intracerebral hemorrhage 9–15% 1, 2, 3
Subarachnoid hemorrhage 1–13% 1, 2, 3
Undetermined type 2–15% 1, 2, 3
Venous infarction < 1% 4, 10
ISCHEMIC STROKE SUBTYPES FREQUENCY REFERENCES
Atherosclerosis of extra- and intracranial arteries 8–50% 1, 2, 5, 6, 7, 9 
Cardiogenic embolism 14–30% 1, 2, 5, 6, 7, 8, 9
Small artery disease 15–30% 1, 2, 5, 6, 7, 9 
Other cause 2–4% 2, 5, 7, 8, 9
Undetermined cause 28–40% 1, 2, 5, 7
1 Sacco et al. 1998 27
2 Foulkes et al. 1988 28
3 Sudlow et al. 1997 29
4 Schaller et al. 2004 30
5 Adams et al. 1993 26
6 Bamford et al. 1991 31
7 Kolominsky-Rabas et al. 2001 32
8 Sandercock et al. 1989 1
9 Warlow et al. 2001 2
10 Daif et al. 1995 33
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Epidemiology of stroke
Cerebrovascular diseases are a major cause of disability in the world and 
ranked as the second leading cause of death in the world during the year 
200234. In the United States, stroke ranks number three among all causes 
of death aft er cancer and heart diseases; on an average, someone dies of a 
stroke in the US every 3 minutes35. In the past (1950–1960), stroke mortality 
in Finland was the highest in western Europe and one of the highest in 
the world36. Furthermore, Finland has had one of the highest reported 
incidence rates of stroke in the world37. However, the 10-year results of the 
FINMONICA stroke study38 showed a marked decline in both the incidence 
of and mortality from stroke in Finland. A continuing reduction has recently 
been reported39, revealing an incidence of approximately 130–140/100000 in 
the FINSTROKE register population in 1997. Th e incidence was higher in 
men than in women. At present, 14000 Finns annually suff er from stroke40, 
which means 38 citizens every day, one fourth of them being at working age41. 
Th is number is increasing, and it has been predicted that the annual number 
of patients suff ering from stroke in 2020 will be about 21,000. Nowadays, 
the prevalence of stroke patients is 50000 in the whole Finnish population, 
and the number of stroke-related deaths per year is 5000.
Cerebrovascular disease is the third most common cause of death in 
Finland, and it is the third most expensive national disease aft er mental 
diseases and dementia. During the year 1999, the direct nursing costs of 
stroke accounted for 6.1% (440 million euros) of the total national health 
care budget42. Every year, 1500 working citizens either die due to stroke 
or lose their ability to work, and 7297 patients were on disability pension 
because of stroke in 1999. Th e loss of earned income every year is 319 million 
euros, and the annual retirement allowances paid due to stroke amount to 83 
million euros42. As the large post-war age classes are approaching the age of 
a high stroke risk (>65 years), the total expenses caused by stroke will grow 
despite the diminishing incidence and improved prophylaxis.
Risk factors of the ischemic stroke
Th ere are several risk factors that are associated with ischemic stroke. 
Advanced age is the major risk factor for stroke, e.g. an 80-year-old person 
has an about 30-fold increased risk of ischemic stroke compared to a 50-
year-old43,44. Among the genders, male sex is a risk for stroke45. Th e most 
important modifi able risk factor for ischemic stroke is increased arterial 
blood pressure, i.e. hypertension. Th e proportional increase in the stroke 
risk associated with a certain increase in blood pressure is similar at all levels 
of blood pressure. Th is risk almost doubles with each 7.5 mmHg increase in 
diastolic blood pressure in western populations (Figure 2)46. Th e relationship 
of stroke with systolic blood pressure is possibly even stronger than that 
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with diastolic pressure. Accordingly, isolated systolic hypertension in the 
presence of normal diastolic blood pressure is associated with an increased 
stroke risk47. Cigarette smoking approximately doubles risk of ischemic 
stroke in males and females in a dose-dependent manner, but the risk is less 
obvious in the elderly48. Cessation of smoking attenuates the risk, and in 5 
years the risk of stroke comes down to the level of never smokers49. Diabetes 
shows about double risk of ischemic stroke50. Randomized trials have not 
shown that treatment of diabetes would reduce the risk of stroke51, yet 
microvascular complications are fewer. Elevated blood lipids are a powerful 
risk factor for coronary heart disease, but their relationship with ischemic 
stroke has been somewhat less clear52–54 55. Recently, a large prospective 
cohort study showed a marked association with total cholesterol and low-
density cholesterol, and increased risk of ischemic stroke in women56. Th e 
AMORIS prospective study demonstrated that the apolipoprotein B to 
apolipoptorein A1 ratio (apoB/apoA-1 -ratio) is a more accurate index of 
the critical balance between atherogenic and atheroprotective lipid particles 
than the conventional cholesterol ratios, and that the apoB/apoA-1 -ratio 
signifi cantly associated with ischemic stroke57. Also the Copenhagen City 
Heart Study revealed that apoB predicts ischemic cardiovascular events 
better than LDL cholesterol, and that in women apoB is associated with 
risk of ischemic cerebrovascular disease58. However, the lowering of 
cholesterol with statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme 
A reductase, HMG-CoA) clearly reduces the stroke incidence59. Physical 
inactivity, obesity, diet, alcohol consumption (none or heavy drinking), race, 
social deprivation, infections60, stress, and specifi c thrombotic conditions 
such as increased plasma fi brinogen, high hematocrit level, high plasma 
factor VII coagulant activity, elevated von Willebrand Factor antigen, low 
blood fi brinolytic activity, high tissue plasminogen activator antigen, and 
hyperhomocysteinemia are also risk factors for ischemic stroke2.
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Figure 2 Relative risk of stroke in relation to diastolic blood pressure (DBP), estimated 
from combined results. Solid squares represent disease risks in each category 
relative to risk in the whole study population; sizes of squares are proportional 
to number of events in each DBP category and 95% CIs for estimates of 
relative risk are denoted by vertical lines. Modifi ed from MacMahon et al. 46.
In addition to pointing out environmental factors, epidemiologic studies 
have also established a genetic infl uence on the susceptibility to stroke. Th is 
infl uence may be divided into rare monogenic disorders (e.g. CADASIL, 
cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy61) and polygenic multifactorial genetic conditions62. 
Th ere is substantial evidence for an inherited risk for stroke: cohort studies 
have revealed that a positive family history of stroke increases the odds of 
suff ering a stroke by 30% (reviewed by Flossmann and colleagues63). It has 
also been observed that a family history of stroke before the age of 65 years 
is a risk factor for stroke, and especially for the large-vessel subtype64. Recent 
research on stroke genetics has discovered two potential risk factor genes: 
phosphodiesterase 4D65 and 5-lipoxygenase activating protein66. However, 
many genetic studies have focused on specifi c polymorphisms, of which 
the genotypes of the apolipoprotein E gene have proven to have functional 
signifi cance, being associated with enhanced recovery aft er stroke67.
It must be noted that, while the list of risk factors is long, many of them 
are not amenable to specifi c therapies (sex, genetics), and while some are 
(hypertension, lipid levels, smoking, etc.), there are still many where specifi c 
treatment has not been shown to reduce stroke incidence.
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Pathophysiology of ischemic stroke
Th e underlying problem in ischemic stroke is the insuffi  ciency or cessation of 
blood supply in the brain mediated by several mechanisms. Ischemia refers 
to a low-oxygen state usually due to obstruction of the arterial blood supply 
or inadequate blood fl ow leading to hypoxia in the tissue. Stroke is a clinical 
syndrome with many underlying conditions, and the particular condition 
present may determine the immediate outcome, have a substantial impact 
on the risk of recurrence, and infl uence long-term treatment. As mentioned 
above, ischemic strokes have been classifi ed into subtypes according to 
the underlying causes (Table1). In population-based studies on Caucasian 
people, about half (50%) of cerebral ischemic events have probably been 
caused by thrombotic and embolic complications of an atheroma, which 
is a disorder of large and medium-sized arteries. About one quarter (25%) 
are related to intracranial small vessel disease, causing lacunar infarctions, 
about one fi ft h (20%) to embolism from the heart, and the rest to rare 
syndromes2,31. 
Apart from arterial ischemia, venous ischemia may also occur, for instance, 
when venous drainage is obstructed, as in sinus thrombosis. Cerebral venous 
thrombosis may occur in either the dural sinus or the bridging veins, and 
in contrast to the sudden onset in the case of arterial thrombosis, venous 
thrombosis usually develops slowly. Th rombosis of the transverse sinus may 
be precipitated by septic conditions, but the underlying pathophysiology of 
venous ischemia is generally not well understood. An increase in intravenous 
pressure is oft en observed, followed by cerebral edema and/or ischemia, but 
cerebral venous occlusion progresses to cerebral venous infarction only in 
approximately 50% of cases. (Reviewed by Schaller and Graf30)
Large-artery atherosclerosis
An atherosclerotic lesion as an indicator of large-artery atherosclerosis is by 
far the most frequent arterial disorder. When complicated by thrombosis and 
embolism, and sometimes by reduced distal fl ow into a severely stenosed 
artery, it is the most common cause of cerebral ischemia and infarction. Th e 
clinically important consequences of an atherosclerotic lesion are probably 
more closely related to the local thrombotic complications of the atherotic 
lesion than the lesion itself. An atherosclerotic lesion aff ects mainly large 
and medium-sized arteries, particularly at points of arterial branching (e.g. 
the carotid bifurcation), and tortuosity. Atherosclerosis is a multifocal rather 
than diff use disease and has typical predilection sites.2 Interestingly, there 
can be severe atherothrombotic stenosis at a particular site on one side of 
the body, but none at all at the corresponding contralateral site68. It has also 
been speculated that, once an atheromatous plaque has been established, its 
growth may become self-promoting as a result of a positive feedback loop, 
driven by either biochemical or hemodynamic factors2.
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Small-vessel disease
Small-vessel disease causes a signifi cant proportion of small, mostly deep-
seated (lacunar) infarcts. Most of what is known of the pathological vascular 
process in lacunar infarction comes from the clinico-anatomical studies by 
Fisher69,70. His fundamental observation was that lacunar infarcts result 
from the occlusion of small perforating cerebral arteries, in some cases by 
a vasculopathic process that he termed “segmental arterial disorganization” 
or “lipohyalinosis” and in other cases by atherosclerosis. Lipohyalinosis 
is a destructive vessel lesion characterized by a loss of normal arterial 
architecture, mural foam cells, and in acute cases, evidence of fi brinoid 
vessel wall necrosis. Vascular lesions appeared in small arteries of 40–200 μm 
diameter and, correspondingly, caused small (3–7 mm in diameter), oft en 
asymptomatic cerebral infarcts, particularly in the striatocapsular regions69. 
Another vascular lesion that has proven relevant to lacune formation is 
intracranial atherosclerosis, which aff ects somewhat larger perforating 
arteries (200–800 μm in diameter), causing larger infarcts, which are more 
oft en symptomatic. Th e culprit atheromatous plaques were seen in the 
proximal portion of the perforating artery (microatheroma), at its origin 
(junctional atheroma), or in the parent artery itself (mural atheroma)69.70 
Microangiopathy, a term oft en used synonymously of small vessel disease, 
refers to a disease process aff ecting the small blood vessels and giving rise 
to white matter changes (leukoaraiosis) in the brain71. Several pathological 
entities may cause damage to small-caliber vessels of the brain, namely 
degenerative “atherosclerotic” changes, amyloid angiopathy, CADASIL, 
and some other rare conditions. Of these, the atherosclerotic type is the 
most common72. Th e principal risk factors for microangiopathy are age and 
hypertension73,74 as well as diabetes mellitus75.
Cardiac embolisms
Cardiac embolisms cause one fi ft h of ischemic strokes. Th ey usually originate 
from the heart, but embolisms passing from the venous system through 
the heart to the brain (paradoxical embolism) are seen as well. Th ere are 
several sources of cardiac embolism, but not all embolisms pose an equal 
threat. Atrial fi brillation (AF), with a clot formed in the left  atrium and then 
being embolized to the cerebral vasculature, is by far the most common 
cause of cardioembolic stroke, accounting for nearly half the cases76. Th e 
average absolute risk of stroke in unanticoagulated non-rheumatic AF 
patients without prior stroke is about 4% per year, being sixfold compared 
to individuals in sinus rhythm77. In the Oxfordshire Community Stroke 
Project, the prevalence of other sources of cardiac embolism were mitral 
regurgitation (6%), recent (<6 weeks) myocardial infarction (5%), prosthetic 
heart valve (1%), mitral stenosis (1%), paradoxical embolism (1%), and other 
sources of uncertain signifi cance (11%)1.
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Pathophysiology of reduced cerebral blood ﬂ ow
Th e brain receives its blood fl ow from two major arterial systems: the 
hemispheres are mostly supplied by the carotid arterial system, whereas 
the posterior parts of the brain are largely supplied by the vertebrobasilar 
system. Physiological cerebral blood fl ow (CBF) is about 50 mL/min/100 g 
brain tissue, of which 80% goes to the grey matter and the rest to the white 
matter78. CBF is normally held at a fairly constant rate by autoregulation 
and can thereby compensate for a wide range of fl uctuations in perfusion 
pressure and cerebrovascular resistance. Ischemia results from an arterial 
obstruction (with venous infarction excluded) that prevents blood fl ow 
to a specifi c area of the brain. Th e residual fl ow depends on the degree 
of obstruction, the condition of the distal arteries, and the availability of 
collateral fl ow. As the amount of fl ow diminishes, the brain compensates 
for this by local vasodilatation and by opening collaterals and increasing the 
fraction of extracted oxygen and glucose. When CBF is reduced to 14–35 
mL/min/100 g tissue, synaptic transmission stops, which decreases brain 
energy use by 50%, and brain tissue cannot tolerate this level of ischemia 
very long. “Teen fl ows” are considered to lead to necrosis within hours. 
Aft er an additional decline in blood fl ow below 4–8 mL/min/100 g tissue, 
a catastrophic ischemic cascade is initiated79. Th is leads to a metabolic 
failure, loss of energy, and neuronal depolarization. Th e resultant release of 
glutamate, entry of Ca2+ into cells, generation of free oxygen radicals and 
nitric oxide, and activation of proteases and phospholipases contribute to 
pathologic changes in neuronal function and structure. Initially, an ischemic 
core develops, where CBF is usually less than 25% of normal. Th e ischemic 
core is surrounded by a penumbra, an area of decreased blood fl ow that may 
be salvaged if the blood supply is restored within few hours. Th e CBF of 
the penumbra is usually 25–50% of normal, which is suffi  cient to maintain 
tissue viability for a limited period80,81.
Carotid system
Th e anterior (carotid) arterial system supplies blood to the anterior and 
middle parts of the brain (Figure 3). Th e left  common carotid artery arises 
from the left  side of the aortic arch, whereas the right common carotid artery 
arises from the brachiocephalic artery. At the level of the thyroid cartilage 
they divide into internal (ICA) and external (ECA) carotid arteries2. ICA 
ascends to the skull base, and along the petrosal section, it gives off  small 
branches which may anastomose with the internal maxillary artery, a branch 
of ECA.2 Th e proximal extracranial part of ICA is commonly aff ected by 
atheroma, and most occlusions are due to rupture and instability of an 
atherosclerotic plaque82. Atheroma may aff ect the ICA in the siphon as 
well. Th e degree of atheroma is not necessarily related to that at the carotid 
bifurcation, and when occlusion occurs in the siphon, it is more likely to be 
due to an embolus from a proximal site than in situ thrombosis82.
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Figure 3 Blood supply to the brain. Th e lower panel indicates the supply territories of 
the main cerebral arteries. Middle cerebral arteries supply the area indicated 
by “M”, anterior cerebral arteries supply the area indicated by “A”, and 
posterior cerebral arteries supply the area indicated by “P”.
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Th e carotid bifurcation is one of the most common predilection sites 
for atheroma development. Transitions in the artery wall confi guration at 
bends and bifurcations are associated with local modifi cations in the rate and 
pattern of blood fl ow, which predispose these regions to the development 
of intimal thickening, including the formation of atherosclerotic plaques83. 
Pulsatile blood fl ow exerts various mechanical forces on the vascular 
endothelium. Th e biologic response to these hemodynamic forces is 
important in atherogenesis. Shear stress and cyclic circumferential strain 
(pulsatile stretch) are two hemodynamic variables that focus primarily 
on the vascular endothelium84, aff ecting endothelial cell turnover85. Shear 
stress is the tangential drag force of blood passing along the surface of 
the endothelium, and its magnitude is directly proportional to blood 
viscosity and inversely proportional to the cube of the vessel radius86. Cyclic 
circumferential strain refers to the distention of a vessel wall due to repetitive 
pulsatile pressure84. Due to hemodynamic forces, intimal thickening and 
plaque formation are most marked in the proximal and mid-sinus sections 
of the internal carotid artery, whereas the common carotid sections show 
slight to moderate intimal thickening, and the distal internal carotid sections 
show only minimal intimal changes83. Th e common carotid shear stress 
varies among healthy individuals and decreases with age, blood pressure, and 
BMI increase87. Th e circumferential wall tension is also directly associated 
with vessel wall thickness, age, and BMI, and shear stress is associated with 
the common carotid intima-media thickness (IMT) independently of other 
hemodynamic, clinical, or biochemical factors87. Moreover, the outfl ow-
to-infl ow ratio (i.e. the ratio of the sum of the cross-sectional areas of the 
branches divided by the cross-sectional area of the parent vessel) is bigger in 
women, and relative to the common carotid artery and the external carotid 
artery, women have larger internal carotid arteries than men, which probably 
partly explains the sex diff erences in the prevalence of carotid plaques88.
Examination of carotid arteries
Transcutaneous ultrasound is a noninvasive and risk-free technique and 
hence ideally suited for serial studies of atherosclerosis progression. It is also 
widely used as a primary method of carotid artery examination. However, 
ultrasound is an operator-dependent modality89,90, and the restricted 
imaging plane of ultrasound can lead to over- or underestimation of disease 
severity91. Especially, there is controversy about the ability of conventional 
2-D ultrasound to identify ulcerated plaques, and the technique of 3-D 
ultrasound has therefore been introduced as a valid and reproducible method 
for the characterization of plaque morphology89,92. Angiography is the most 
accurate method to detect arterial stenosis, and it can be carried out by 
computed tomography (CTA), magnetic resonance angiography (MRA), 
or digital subtraction angiography (DSA), which results in the most precise 
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and best-quality imaging. MRA may overestimate high-grade stenosis due to 
consequent slow blood fl ow93, but it is noninvasive and radiation-free, and 
is hence considered a good method for studying the early lesions of carotid 
atherosclerosis94. DSA carries a 1% risk for permanent neurological defi cit, 
with a mortality rate of 0.1%95. In addition, early lesions may be accompanied 
by compensatory (expansive) remodeling that normalizes the area of the 
vessel lumen, making the detection of these lesion types impossible by 
DSA96. Although noninvasive studies can be extremely accurate in the initial 
evaluation of a patient with carotid disease, angiography is usually needed 
before a decision is made about surgical treatment95.
Management of carotid stenosis
Surgical treatment
Th e treatment of choice for patients with symptomatic high-grade (70–99%) 
stenosis is carotid endarterectomy4. In the NASCET trial4, the absolute risk 
reduction (±SE) for all ipsilateral strokes at two years was 26±8.1% among 
patients with stenosis of 90–99% at entry, 18±6.2% among those with stenosis 
of 80–89%, and 12±4.8% among those with stenosis of 70–79%. For all high-
grade symptomatic lesions (70–99%), there was a 17% absolute reduction 
in the risk of ipsilateral stroke at two years. Th is also proves the paramount 
importance of carotid artery disease as the culprit lesion in stroke patients 
who have been carefully clinically evaluated. Th e perioperative risk for major 
stroke and death was 2.1%, and the fatality rate in the NASCET study was 
0.6%. In the European Carotid Surgery Trial (ECST)3, the absolute benefi t 
in terms of major strokes and all deaths was 11.6%, which means that 116 
major strokes or deaths from any cause might be avoided per 1000 patients 
with symptomatic stenosis of 80–99% treated surgically during three years 
of follow-up. Th ere are three factors that are mainly responsible for the 
benefi t derived from endarterectomy: i) the degree of carotid stenosis, ii) 
the presence or absence of thromboembolic symptoms, and iii) the rate of 
perioperative complications97. Th e benefi t of endarterectomy diminishes 
rapidly when the rate of surgical complications exceeds 2.1%, and completely 
vanishes when the rate approaches 10%. It is therefore important to allocate 
the procedures to surgical centers with proof of a high level of expertise4.
In the case of asymptomatic carotid lesions, the benefi t of endarterectomy 
has not been verifi ed98. Th erefore, the ACAS (Asymptomatic Carotid 
Atherosclerosis Study) trial10 was conducted in 1987–1993. It showed 
that patients with asymptomatic carotid artery stenosis of 60% or greater 
reduction in diameter whose general health makes them good candidates 
for elective surgery will have a reduced 5-year risk of ipsilateral stroke 
if carotid endarterectomy is performed with less than 3% perioperative 
morbidity and mortality, and is combined with aggressive management of 
modifi able risk factors.
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In the standard procedure of carotid endarterectomy, the carotid 
bifurcation is exposed and gently mobilized, and slings are placed around 
the internal, external, and common carotid arteries. Aft er applying clamps 
to these three arteries away from any atheromatous plaque, the bifurcation 
is opened through a longitudinal incision. Th e entire stenotic lesion is 
cored out, aft er which the distal intimal margin is secured, the arteriotomy 
is closed, and the clamps are released to restore blood fl ow to the brain. 
Th e plane of dissection is usually between the media and the external 
elastic lamina situated at the beginning of the adventitia.2,99 A less invasive 
procedure to treat carotid stenosis is endovascular angioplasty and stenting, 
but a recent study showed that the 30-day risk of any stroke or death was 
signifi cantly higher aft er stenting (9.6%) than aft er endarterectomy (3.9%)100. 
But comparative studies between CEA and angioplasty are ongoing (e.g. 
CAVATAS II)101.
Noninvasive therapy
If surgery is not feasible for some reason, the therapy of carotid stenosis 
consists of management of modifi able risk factors and pharmacotherapy. 
Th e treatment of risk factors includes adequate management of arterial 
hypertension, diabetes mellitus, and hypercholesterolemia as well as 
cessation of smoking and loss of weight in case of obesity. Preliminary 
evidence suggests also that clinically diagnosed chronic infections 
should be treated, and patients with high risk of stroke should receive an 
infl uenza vaccination annually102. If the patient has symptomatic vascular 
disease, there is clear benefi t from the use of antiplatelet therapy (ASA, 
dipyridamole, clopidogrel)103. Th ere has been debate about whether patients 
with asymptomatic carotid stenosis have a suffi  ciently high risk of stroke to 
justify antiplatelet drugs104. Anticoagulants seem to play a small role in the 
medical treatment of carotid stenosis105, but they are sometimes used in the 
case of critical carotid stenosis, particularly before endarterectomy.
ATHEROSCLEROSIS
General aspects
An atherosclerotic lesion is the most common acquired abnormality of 
blood vessels. It develops in the intima against a background of smooth 
muscle cells, blood-derived white blood cells, and a variable amount of 
connective tissue.106 Th e main features of an atherosclerotic lesion are the 
accumulation of cholesterol in the intima, an infl ammatory response with 
collection of infl ammatory cells (monocytes, T cells and mast cells) and 
cytokine production, and the proliferation of intimal smooth muscle cells2,106. 
Atherogenesis in humans develops over years, generally even decades. Early 
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lesion formation may occur in adolescence (fatty streaks). Th e progression 
of an atherosclerotic lesion depends on the individual’s genetic background, 
gender, and certain well recognized as well as some non-traditional risk 
factors. Complications that precipitate acute manifestations of atherosclerosis 
occur suddenly. Some individuals with this disease may never experience 
symptoms, and some may endure chronic stable manifestations whilst 
evading complications. Still others may suff er grave or fatal acute events, 
like sudden death, with no prior warning14.
Atherosclerotic lesions were histologically classifi ed by a Committee 
on Vascular Lesions (the Council on Arteriosclerosis, American Heart 
Association, AHA)107–109, and this classifi cation was updated in 2000110. 
According to the original AHA classifi cation, there are six histologically 
diff erent classes as follows (Figure 4): In type I lesions isolated macrophage 
foam cells are found, in type II lesions multiple foam cell layers are formed, in 
type III lesions additional isolated extracellular cholesterol pools are found, 
in type IV lesions a confl uent extracellular lipid core is formed, in type V 
lesions fi bromuscular tissue layers are produced, and in type VI lesions either 
surface defect exists or a hematoma or thrombosis (or both) develops.
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Figure 4 Atherosclerotic lesions according to the AHA classifi cation. In type I lesions eccentric 
intimal thickening and isolated macrophage foam cells are found, in type II lesions multiple 
foam cell layers are present, in type III lesions extracellular lipid pools are formed, in type 
IV lesions a confl uent extracellular lipid core is formed, and in type V lesions fi bromuscular 
tissue layers are produced. Th e type VI represents a complicated lesion, where a surface 
defect is present, and oft en a fi ssure and intraplaque hematoma are found leading to 
thrombus formation.
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Atherosclerotic artery
Healthy vessel wall
Th e arterial wall is composed of three distinct layers: intima, media, and 
adventitia. Th e inner lining, intima, comprises a single layer of extremely 
fl attened epithelial cells, called endothelium, and is supported by a basement 
membrane composed of delicate connective tissue and smooth muscle cells. 
In a healthy vessel, the intima is usually very thin, and the majority of smooth 
muscle cells are of the contractile phenotype. Th e media is the intermediate 
muscular layer, which is surrounded by the external elastic lamina followed 
by the outer connective tissue layer called the adventitia. Th e intima consists 
mainly of smooth muscle cells, which are the main source of extracellular 
matrix, and scattered fi broblasts and other cells with ultrastructural features 
akin to smooth muscle cells and known as myointimal cells. Th e intima is 
also the location where atherosclerotic lesions are targeted. Th e media is 
composed of contractile smooth muscle cells criss-crossed by elastic fi bres. 
Small blood vessels, i.e. vasa vasorum, make up a capillary network that 
supplies oxygen and nutrients within the adventitia.111
Atherosclerotic vessel wall
Endothelial cells (ECs) fulfi l a number of physiological functions, 
including the provision of a permeability barrier, a non-thrombogenic 
surface, and a mediator of vascular tone and the production of a number 
of molecules in response to infl ammatory and immune stimuli107. A key 
event in the evolution of atherosclerotic plaques is thought to be injury or 
dysfunction of the endothelium11. As a consequence of several extrinsic 
stimuli, EC activation begins, featuring organelle hyperplasia as a sign of 
immunological activation. It is estimated that 5% of ECs express class II 
antigens. Furthermore, as a probable indication of senescence, ECs may 
develop into giant cells (surface area ≥ 800 μm2).112 During the evolution of 
atherosclerosis, EC injury may lead to apoptosis, i.e. programmed cell death, 
which results in endothelial denudation12,13. Th ere is substantial evidence 
that many endothelial processes are sensitive to the presence of lipids. Both 
LDL and triglyceride-rich lipoproteins, like small-sized very low density 
lipoproteins (VLDL), impair endothelium-dependent vasodilatation and 
stimulate the adhesion of leukocytes to the endothelial surface, promoting 
leukocyte adherence and migration113. Perturbations in the physiological 
EC functions arise secondary to a large number of underlying mechanisms 
and may contribute to the development of atherosclerosis by shift ing the 
balance from vasodilatory to vasoconstrictory state, favoring recruitment 
of leukocytes to the vascular wall, loss of endothelial protection against 
inappropriate thrombosis, and failure of fi brinolysis113. (Figure 5)
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Figure 5 Vascular injury, entry of lipids, and infl ammation. During the initial phases of 
atherosclerosis, endothelial cells become activated and begin to express diverse molecules, 
e.g. adhesion molecules, on their surface and enable leukocyte, especially monocytes, 
and LDL entry into the vascular wall. Infl ammatory cells secrete cytokines, which induce 
infl ammatory and oxidative reactions and cause smooth muscle cell proliferation, i.e. 
change in phenotype from contractile to synthetic, within the vessel wall. Later in the 
course of atherosclerosis, the endothelial lining is injured, permitting a thrombus to be 
formed. Abbreviations: LPS = lipopolysaccharide, IL-1β = interleukin 1 beta, TNFα = 
tumor necrosis factor alpha, ICAM-1 = intercellular adhesion molecule 1, VCAM-1 = 
vascular cell adhesion molecule 1, LDL = LDL-cholesterol, mLDL = modifi ed LDL .
Th e endothelium exerts a major infl uence on the underlying vascular 
smooth muscle, not only via the release of both contracting and relaxing 
factors but also by its ability to synthesize a large number of molecules that 
infl uence vascular smooth muscle growth. In vitro, ECs inhibit VSMC DNA 
synthesis114, which is consistent with the observation on entire vessels, where 
the endothelium counteracts the eff ect of growth promoters, and when 
mature vessels are denuded of EC, the normally quiescent VCMSs exhibit 
a marked increase in their proliferation rate115.
Th e intima is the cell layer principally involved as an arena for the 
development of atherosclerosis, although secondary changes are occasionally 
seen in the media16,17. Changes in the phenotype and number of intimal 
smooth muscle cells are observed during the initial phases of atherosclerosis. 
Th eir phenotype is changed from contractile to a synthetic one116. 
Vascular smooth muscle cells (VSMC) possess an ability to regress to a less 
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diff erentiated phenotype under circumstances of cell culture, injury, and 
atherogenesis. Such phenotypically modulated VSMCs have a decreased 
volume fraction of myofi laments. Th ey lose their ability to contract, but 
instead migrate and proliferate readily in response to growth factors and 
cytokines and also synthesize large amounts of matrix proteins117–119. It has 
been debated as to whether the proliferation of VSMCs is derived from a 
single VSMC that serves as a progenitor for the remaining proliferative 
cells120. Another hypothesis is that plaque (intimal and medial) VSMCs are 
distinctly diff erent VSMC cell types121. Or the diff erent phenotypes may 
just represent diff erent states of activity and susceptibility to mitogens11. 
VSMCs synthesize a number of proteins: collagens, elastin, proteoglycans, 
and glycosaminoglycans122. Together, VSMCs and the extracellular matrix 
components may form a fi brous cap that covers the plaque if endothelial 
denudation occurs16.
Lipids and atherosclerosis
Elevated levels of blood lipids (mainly cholesterol) are unique in being 
suffi  cient to drive the development of atherosclerosis even in the absence 
of other risk factors123. Th e earliest lesion in the intima of an atherosclerotic 
artery is a fatty streak, which is characterized by a focal accumulation of 
relatively small numbers of intimal smooth muscle cells and macrophage 
foam cells, containing and surrounded by lipids, mainly in the form of 
cholesteryl esters and free cholesterol11,16. Th e accumulation of these lipid-
laden foam cells, which is the hallmark of fatty streaks, may be reversible 
via reverse cholesterol transport, but it sets the stage for the progression of 
atheroma.14 Th e cholesterol pool of the body is derived from the absorption 
of dietary cholesterol and de novo biosynthesis of cholesterol in liver124. 
Lipids are bound in complex lipoprotein particles, that consist of a core 
of neutral lipids (triglycerides and/or cholesterol esters), surrounded by 
phospholipids and unesterifi ed cholesterol, and covered partly by the protein 
component; apolipoprotein125. Diff erent combinations of lipid and protein 
produce diverse lipoprotein particles. Apolipoprotein A (apoA-1) is mainly 
associated to high-density lipoprotein (HDL)126, and apolipoprotein B (apoB) 
to low-density lipoprotein (LDL)125.
When plasma LDL levels are high, the dysfunctional endothelium permits 
the entry of LDL within the subendothelial space127, and when the retention 
time increases, oxidation of LDL, as well as other types of LDL-modifi cation, 
by free radicals produced by adjacent cells may ensue128,129. Oxidized LDL 
(oxLDL) is highly atherogenic130 and has a defi nite role in atherosclerosis131. 
OxLDL may act as a chemoattractant for circulating human monocytes132. 
Lipids have also been shown to have an eff ect on various endothelial 
processes, and they impair endothelium-dependent vasodilatation113. 
OxLDL is internalized by scavenger receptors on the surface of VSMCs 
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and particularly macrophages, resulting in the formation of foam cells 133. 
Lipoproteins, particularly LDL, can also diff use directly from blood into 
the arterial intima, forming lipid deposits134. Although modifi cation of 
LDL particles seems to be the most important generator of the cholesterol 
imbalance resulting in the accumulation of lipids within the plaque135, 
intraplaque hemorrhages also appear to be a source of cholesterol136,137, 
since extravasated erythrocytes can carry cholesterol in their membranes 
into the plaque138.
Evidence suggests that oxidative modifi cations in the lipid (cholesterol, 
phospholipids) and apo B components of LDL lead to the initial formation 
of fatty streaks139 and are also an important cause of infl ammatory reactions 
within the lesion123. Th e specifi c properties of oxLDL depend on the extent 
of modifi cation, which can range from minimal modifi cation (mmLDL, 
minimally modifi ed LDL) to extensive oxidation, which causes the 
apolipoprotein B component fragmented into reactive breakdown products. 
MmLDL is still recognized by LDL receptors, but severily oxidized LDL is 
bound to several scavenger receptors, e.g. the scavenger receptors A (SR-A) 
and CD36139–141. OxLDL-derived cholesterol within the macrophage consists 
of free cholesterol and cholesterol esters that are hydrolyzed in lysosomes. 
Free cholesterol may be esterifi ed by acyl CoA:cholesterol acyltransferase-1 
(ACAT-1) or stored in the lipid droplets that characterize foam cells. 
Th e mechanisms that mediate the cholesterol effl  ux from macrophages 
are critical in maintaining cholesterol homeostasis in macrophages, and 
macrophages have three primary mechanisms for disposing of excess 
cholesterol: i) effl  ux via specifi c ATP-driven membrane transporters (e.g. 
ABCA1 and ABCG1142–144) which mediate cholesterol removal to apoA-1 on 
spherical high-density lipoprotein (HDL) particles, ii) effl  ux via scavenger 
receptor B type I (SR-BI) to HDL145, and iii) effl  ux via passive diff usion 
of cholesterol to HDL146. Th is process is known as “reverse cholesterol 
transport”.123 Th e role of oxLDL has also been discussed as a mediator of 
immune activation within atherosclerotic lesions, since it has been found 
that specifi c epitopes of oxLDL exist, and a positive correlation between 
autoantibodies against these oxLDL epitopes and the extent of atherosclerosis 
has also been observed (reviewed by Hörkkö and coworkers147). However, it 
has not yet been established whether the presence of autoantibodies against 
oxLDL acts as a marker, or whether it has clinical signifi cance123, since there 
are also studies that fail to confi rm the presence of an association between 
these autoantibodies and atherosclerosis148,149.
Lipid droplet proteins – adipophilin
Lipids may be stored within cells in the form of droplets surrounded by lipid 
droplet proteins. Structurally, these proteins may be divided into at least 
two classes, of which one includes perilipins and adipophilin (an adipocyte 
diff erentiation-related protein, ADRP).150 Adipophilin expression has been 
32
observed in several cell types that store lipid, which implies that it has an 
essential role in lipid metabolism, possibly in the nucleation of neutral lipid 
packaging151. Th e precise function and signifi cance of adipophilin are not 
known, nor is it known whether it merely refl ects the mass of stored neutral 
lipid within the cell152, but it may have a biological function in the deposition 
and transport of cytosolic lipid droplets and in lipid packaging153. Larigauderie 
and coworkers found that adipophilin enhances lipid accumulation and 
prevents lipid effl  ux from macrophages, which suggests a potential role in 
atherogenesis154. OxLDL has been found to induce adipophilin expression in 
macrophages, suggesting a role for adipophilin in foam cell formation155.
Inﬂ ammation and adhesion molecules
Atherosclerosis is an inﬂ ammatory disease
Atherosclerotic lesions represent a series of highly specifi c cellular and 
molecular responses that can best be described as an infl ammatory 
disease15,156. Th e recruitment of mononuclear leukocytes to the intima is one 
of the earliest events in the formation of an atherosclerotic lesion14,15. Once 
ECs are activated and become dysfunctional, they permit infl ammatory cells 
to enter the vessel wall by means of specifi c adhesion molecules expressed 
on the surface of vascular ECs157,158. Th is occurs along the simultaneous 
entry of lipids mainly in LDL form. In addition to adhesion molecules, 
there are molecules associated with the migration of leukocytes across 
the endothelium, acting in conjunction with chemoattractant molecules 
generated by the endothelium, smooth muscle, and monocytes to attract 
monocytes and T cells into the artery15. Infl ammation is considered the 
major fi nal part of the pathway converting the eff ects of risk factors into 
changes in the biology of the arterial wall159,160.
Th e predominant infl ammatory cell in an atherosclerotic lesion is the 
lipid-laden macrophage, or foam cell. Th ese cells develop from monocytes, 
which are the primary eff ectors of the innate arm of the infl ammatory 
immune response159. In response to specifi c stimuli, macrophages become 
activated, either “classically” triggered by products of activated T helper 1 
(TH1) type lymphocytes, natural killer (NK) cells, or cytokines involving e.g. 
IL-12 and IL-18. Another pathway of macrophage activation is “alternative” 
activation by IL-4 and IL-13 cytokines that are generally produced in TH2 
type lymphocyte responses (reviewed by Gordon161). Th e exact role of these 
diff erent macrophage activation pathways is not yet known, but it has been 
speculated that TH2 cytokines, possibly by acting through alternatively 
activated macrophages, could promote plaque stability161. However, other 
classes of leukocytes, such as T and B lymphocytes and mast cells, also 
accumulate in the arterial intima during atherogenesis162,163. Th e T cells 
within atherosclerotic lesions are usually CD4+ T cells, which recognize 
antigens present on major-histocompatibility-complex (MHC) class II 
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molecules. Th ere are also a few natural killer (NK) T cells, which recognize 
lipid antigens, and CD8+ T cells restricted by MHC class I antigens.164 
Neutrophils are the major component of the innate immune system and 
present in circulation primarily in acute infl ammation165. Th ey are not 
usually found in stable atherosclerotic lesions, but occasionally occur in 
ruptured or eroded coronary plaques166.
Cellular adhesion molecules
Activated endothelial cells express several types of leukocyte adhesion 
molecules, which cause blood cells to attach to the vascular endothelial 
surface. Subsequently, chemokines produced in the subendothelial layers 
stimulate infl ammatory cells to migrate through the endothelium to the 
intima (Figure 5). Th e expression of cellular adhesion molecules is an 
important element in the infl ammatory component of atherosclerosis and 
contributes to monocyte and lymphocyte recruitment to the vessel wall22,167. 
Th e four major classes of adhesion receptors are the immunoglobulin 
superfamily, integrins, selectins, and cadherins (Table 2).157
Two important adhesion molecules that belong to the immunoglobulin 
superfamily are ICAM-1 and VCAM-1, which bind to the integrin receptors 
found on the membranes of e.g. leukocytes, and both of which mediate 
monocyte and lymphocyte adherence157,168,169. Adhesion molecules are also 
expressed within the atherosclerotic lesion, especially on smooth muscle 
cells, and it has been postulated that particularly ICAM-1 contributes to 
smooth muscle cell migration and proliferation not only in neointima 
formation but also in atherosclerosis170. ICAM-1 expression by smooth 
muscle cells appears to be phenotype-dependent, and it associates with 
a less diff erentiated phenotype of VSMCs171. Th is indicates the existence 
of complex regulatory mechanisms; ICAM-1 may be regulated by the 
cytoskeletal apparatus, a hypothesis supported by the observation that 
ICAM-1 interacts with α-actinin172. ICAM-1 expression has been observed 
on the endothelium of atherosclerotic lesions by several research groups173, 
and it has been associated with the destabilization of the plaque23,174. In 
addition to its role in the infl ammatory response, ICAM-1-mediated signal 
transduction may lead to immune responses175, and it also has a role in 
the infl ammatory cell response in focal brain ischemia176. VCAM-1 has 
also been implicated in atherosclerosis177,178, and VCAM-1 blockade by 
siRNA approach has been eff ective in reducing T cell adhesion in vascular 
endothelial cells in a mouse model179.
Selectins are another important group of adhesion molecules that interact 
with carbohydrate ligands, mediating the initial rolling of leukocytes along 
the endothelium. Th ree selectins, L-selectin, P-selectin, and E-selectin, act 
in concert with other cell adhesion molecules to mediate interactions of 
leukocytes, platelets, and endothelial cells.158,180 P-selectin is synthesized 
and stored in platelets and endothelial cells, and its expression is short-lived, 
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declining within minutes. Th e expression of E-selectin is mainly restricted 
to activated endothelial cells, and its expression diminishes within a few 
hours.180 It has been suggested that P- and E-selectins together play a role in 
atherosclerotic lesion development, since P- and E-selectin double-defi cient 
mice had signifi cantly smaller atherosclerotic plaques than wild-type mice 
on an atherogenic diet181. In human studies, P-selectin has been found to be 
increased in patients with unstable compared to stable angina182.
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Table 2. Primary adhesion molecules and their functions.
FAMILY / NAME MAJOR FUNCTIONS LIGAND / 
BINDING
SOLUBLE
FORM
REFERENCES
IMMUNOGLOBULIN
SUPERFAMILY
Leukocyte binding and extravasa-
tion, fi rm cellular adhesion
1, 2 
     ICAM-1 Firm adhesion αLβ2, αMβ2, αXβ2 + 1, 4 
     ICAM-2 Firm adhesion αLβ2, αMβ2 + 4
     ICAM-3 Firm adhesion αLβ2, αDβ2, DC-SIGN + 4
     VCAM-1 Firm adhesion α4β1 , α4β7, αDβ2 + 1, 4
     PECAM-1 Migration of leukocytes ac-
cross endothelium, endothelial 
integrity
PECAM-1, 
αVβ3
+ 1, 4
     N-CAM Induces outgrowth of neurites N-CAM, 
Fibroblast 
growth fac-
tor receptor 
(FGFR)
+ 1
INTEGRINS
Signaling events, cellular processes, 
e.g. proliferation, inhibition of apop-
tosis, gene expression, cell migration 
and spreading, secretion and activa-
tion of other receptors
1
     α5β1 Support the assembly of fi bronectin 
matrix
Fibronectin 
(FN)
- 1, 4 
     α4β1 Firm adhesion VCAM-1, FN - 1, 4 
     α4β7 VCAM-1 - 1, 4 
     αIIbβ3 Platelet receptor, platelet aggrega-
tion, recruitment of neutrophils and 
monocytes
Von Willebrand 
Factor (VWF), 
FN, Vitronectin 
(VN), Th rom-
bos-pondin, Fi-
brinogen (FG)
- 1, 2, 4 
     αVβ3 Proliferation, migration PECAM-1,  
VN, FN, FG, 
VWF
- 2, 4 
     αVβ5 Proliferation, migration VN - 4 
     αDβ2 Firm adhesion ICAM-3, 
VCAM-1
- 4 
     αMβ2 Firm adhesion ICAMs, iC3b, 
Factor X, FG
- 4 
     αXβ2 Firm adhesion ICAM-1, FG, 
iC3b, CD23
- 4 
     αLβ2 Firm adhesion ICAMs - 4 
     α2β1 Platelet receptor Collagen, 
Laminin
- 2, 4 
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SELECTINS
Functions in vascular and hemato-
logic systems, a key role in regulat-
ing the movement of leukocytes 
from the blood into tissues, binding 
of circulating leukocytes, part in 
leukocyte rolling and tethering
1, 2
     P-selectin Platelet rolling, binding to multi-
ple leukocyte types
P selectin lig-
and 1 (PSL-1), 
sialyl-Lewis 
x and a (sLex 
and sLea), 
CD24 
+ 1, 3, 4 
     E-selectin Important in binding and migra-
tion of leukocytes
E selectin lig-
and 1 (ESL-1), 
PSL-1, L-set, 
sLex and sLea
+ 2, 3, 4 
     L-selectin Adhesion of neutrophils, mono-
cytes and lymphocytes, mediates 
homing of lymphocytes to lymph 
nodes
sLex, CD34, 
PSL-1, Gly-
CAM
+ 2, 3, 4  
CADHERINS
Molecular links between adjacent 
cells, e.g. adherens junctions, cell 
migration and tissue diff erentia-
tion in embryos, signaling through 
catenins
1 
     N-cadherin Mediates outgrowth of neurites N-cadherin + 1 
     E-cadherin Suppresses local invasiveness 
and distant metastasis in some 
cancers
E-cadherin + 1 
     VE-cad-
     herin
Control of vascular permeability 
and vascular integrity
VE-cadherin + 5
1 Frenette et al. 158
2 Frenette et al. 157
3 Bevilaqua et al. 180
4 Blankenberg et al. 183
5 Dejana et al. 184
Circulating adhesion molecules, particularly ICAM-1, VCAM-1, and E-
selectin, have been detected in plasma, and their concentrations are elevated 
in infl ammatory conditions. Th eir origin is unclear, but it has been suggested 
that they arise via shedding or proteolytic cleavage from endothelial cells.185 
Soluble forms of ICAM-1 and E-selectin were found to predict carotid artery 
atherosclerosis and coronary heart disease in the ARIC study186. Circulating 
adhesion molecules have also been reported to be associated with carotid 
atherosclerosis or acute cerebral ischemia187–189, an elevated risk of ischemic 
stroke190, or carotid intima-media thickness191.
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Cellular apoptosis
Apoptosis is an active quality-controlled form of cell death that is elaborately 
regulated and distinct from necrosis. While necrosis refers to a non-energy-
consuming series of events that leads to the death of the cell, apoptosis is an 
energy-consuming, programmed, and highly selective mechanism of cell 
death that allows the removal of redundant or injured cells192. Apoptosis 
is considered to be a physiological phenomenon that is important in many 
biological events, including morphogenesis, cell turnover, and the removal 
of harmful cells193. Apoptosis ensues from the activation of eff ector proteases 
called caspases (cysteine aspartic acid proteases), which participate in the 
cascades eventually leading to cell death194,195. Cells undergoing apoptosis 
are packed in smaller particles that are engulfed by surrounding phagocytic 
cells, mainly macrophages.
Th ere are two major pathways of apoptosis: the extrinsic pathway, which is 
transmitted by the TNF (tumor necrosis factor) superfamily, and the intrinsic 
pathway, which is mitochondria-associated (Figure 6). In the extrinsic 
pathway, apoptosis ensues from the binding of a specifi c ligand to a cell 
surface receptor, which can be one of the six death receptors (DR) known 
today: FasR, TNFR1 (tumor necrosis factor receptor 1), DR3, DR 4 (TRAIL-
R1 or receptor to TRAIL or TNF-related apoptosis-inducing ligand), DR5 
(TRAIL-R2), and DR6, with an additional member of the TNFR superfamily, 
CD40193. Each of the receptors have an intracellular death domain (DD) 
that further communicates the death signal to caspases, especially to the 
executioner caspases (caspases 3, 6, and 7)196, and eventually leads to the 
activation of caspase 3 (CASP3), giving rise to apoptotic cell death197.
Th e intrinsic pathway of apoptosis involves mitochondria, i.e. the site of 
oxidative metabolism. Activation of the mitochondrial pathway of apoptosis 
does not require the involvement of cell membrane death receptors, but 
several stimuli may trigger the release of cytochrome c (a heme protein 
associated with the inner leafl et of the mitochondrion and an essential 
component of the electron transfer chain198) from the mitochondria to 
the cytosol, leading to the formation of an apoptosome, a large complex 
containg Apaf-1 (apoptotic protease activating factor 1), procaspase 9, 
and dATP, and further leading to the activation of caspase 9 (CASP9) and 
CASP3 in that order.193,199 Th e release of cytochrome c from mitochondria 
is strictly regulated by the BCL-2 family of proteins, which exist in both 
pro- and antiapoptotic forms. Th e BCL-2 family has three subfamilies: 1) the 
antiapoptotic proteins represented by Bcl-2 and Bcl-xL, 2) the multidomain, 
proapoptotic proteins, including Bax and Bak, and 3) the “BH3 domain 
only” proteins, which are proapoptotic proteins represented by tBid, Bad, 
and Bik. It has been speculated that the fate of a cell is largely determined 
by which of these subfamilies is overrepresented.200
38
Figure 6 Main pathways of apoptosis. Th e death receptor-mediated pathway of 
apoptosis is presented on the left  side of the chart and the mitochondrial 
pathway of apoptosis on the right side. Abbreviations: FasL = FasLigand, 
TNF-α = tumor necrosis factor -alpha, TRAIL = TNF-related apoptosis 
inducing ligand, TNFR1 = TNF-receptor 1, DR3, 4, 5 = death receptor 3, 
4, 5, TRAIL-R1, -R2 = TRAIL receptor 1, 2, FLIP = Fas-associated death 
domain-like interleukin-1-converting enzyme inhibitory protein, DD = death 
domain, casp = caspase, IAPS = inhibitors of apoptosis family of proteins, Cyt 
C = cytochrome c, PARP = poly(ADP-ribose) polymerase.
Implications of apoptosis in atherosclerosis and the Fas pathway of 
apoptosis
Th ere is a large body of evidence suggesting a role for apoptosis in 
atherosclerosis and the progression of atheroma20,201–209. VSMCs and ECs 
encounter a number of biologically active factors, including mechanical 
force210,211, oxidative stress212, reactive oxygen species (ROS)213, lipids214,215, 
and infl ammatory cytokines216,217. Apoptosis of ECs may lead to the initiation 
of endothelial damage and create a prothrombotic environment amplifying 
an infl ammatory response12. EC apoptosis may increase VSMC proliferation 
and migration and increase leukocyte infi ltration218. Apoptosis of VSMCs 
has been observed in atherosclerotic plaques219, and it has been linked to 
interactions with macrophages220. Th e death of VSMCs may be detrimental 
by leading to weakening of the fi brous cap, since VSMCs produce most of the 
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interstitial collagen fi bers221,222. Apoptosis of infl ammatory cells may have 
diverse eff ects: Apoptosis of macrophages may suppress the development of 
atherosclerosis223, but on the other hand, their apoptosis may liberate free 
lipid to the plaque and release TF (tissue factor) in lipid-rich plaques, with 
consequent thrombotic complications224.
Of the members of the TNF superfamily, the FasR-FasL receptor-ligand 
pair is the best-characterized and most widely studied. FasR (CD95 or 
APO-1) is a 45 kDa transmembrane protein, which is ubiquitously expressed 
on a variety of normal cells, and FasL is a 40 kDa glycoprotein whose 
expression is somewhat limited.225 Th e apoptotic pathway is initiated when 
the Fas-associated death domain (FADD) and caspase-8 (FLICE) bind 
with multimerized FasR to form the death-inducing signaling complex 
(DISC)226,227. Caspase 8 then further communicates the death signal to 
the executioner caspases, and this eventually leads to the activation of 
CASP3, giving rise to manifest apoptosis197. FasL can be cleaved from the 
cell surface by matrix metalloproteinases (MMPs), and this is believed to be 
the mechanism for turning off  apoptosis in bystander cells228. Th e primary 
function of FasR is in the attenuation of immune responsiveness through the 
deletion of activated peripheral lymphocytes229, but FasR and ligation to its 
cognate ligand FasL have been implicated in atherosclerosis as well230–232.
Expression of both FasR and FasL has been detected in normal and 
diseased vessel wall, and Fas-mediated apoptosis has been proposed as a 
feature of atherogenesis214,233. Increased expression of FasR in the intima of 
atherosclerotic arteries has been suggested to be involved in the induction of 
VSMC apoptosis230. FasL expression has also been observed on endothelial 
cells231, where their presence has been suggested to be protective against 
infl ammatory cells234. It has also been observed that overexpression of 
FasL on allograft  endothelium inhibits infl ammatory cell infi ltration and 
intimal hyperplasia235, and that, in rats, FasL gene transfer to the vessel wall 
inhibits neointima formation236. Th e postulated benefi cial eff ect of FasL in 
atherosclerosis has, however, been disclaimed by other research groups. For 
example, Schneider and colleagues232 observed that the expression of FasL 
in the arteries of hypercholesterolemic rabbits accelerated atherosclerotic 
lesion formation. In addition, FasL may promote the infl ammatory response 
by inducing the secretion of pro-infl ammatory cytokines from FasR-bearing 
infl ammatory cells aft er the activation of the caspase cascade237.
Intraplaque microhemorrhages
Neovascularization of the intima and involvement of vascular endothelial 
growth factor (VEGF) is a dominant feature of plaque development in 
atherosclerosis238, and the molecular mechanisms primarily responsible 
for neovessel formation are related to hypoxia239. Local microhemorrhages 
of neovascularization that occur within atherosclerotic plaques have 
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been suggested to play a causative role in carotid plaque rupture240,241. 
Microhemorrhages initiate erythrocyte phagocytosis leading to iron 
deposition, macrophage activation, and foam cell formation241. Iron is 
capable of inducing oxidative damage within atherosclerotic plaques by 
catalyzing oxidative modifi cations of LDL242, and free hemoglobin (Hb) 
can also induce oxidative tissue damage by virtue of its heme iron and 
subsequent production of ROS. Th e primary mechanism of removal of free 
Hb is provided by the protein haptoglobin (Hp), which rapidly binds to Hb, 
forming a Hp-Hb complex. In the extravascular compartment the Hp-Hb 
complexes are cleared by macrophages by means of a scavenger receptor 
CD163243 (Figure 7). Free iron is bound to transferrin (Tf), the di-ferric Tf 
binds to the Tf receptor (TfR), and this complex is endocytosed within the 
cell into the endosome. Th e iron exported in the endosome into cytosol can 
be used in a variety of cellular processes or detoxifi ed by incorporation into 
cytosolic ferritin.244
Scavenger receptor CD163
In addition to its role in clearing Hp-Hb complexes, CD163 has other 
functions as well: the cross-linking of CD163 with the Hp-Hb complex has 
an immunomodulatory role by controlling the expression of pro- and anti-
infl ammatory cytokines that have diff ering roles in atherosclerosis245,246. 
CD163 has been considered to be a marker of alternative activation of 
macrophages161. Since there is functional polymorphism in the haptoglobin 
gene, the eventual eff ect of intraplaque hemorrhages on macrophage 
activation mediated by the interaction of CD163 and the Hb-Hp complex 
may be determined by the haptoglobin genotype247. Th ere are two classes 
of alleles, Hp-1 and Hp-2, and the larger size of Hp-2 may impair its ability 
to reach the site of hemorrhage248. Furthermore, the Hp-1 allele protein 
product is superior to the Hp-2 allele protein in preventing Hb-induced 
oxidative stress249 and the formation of ROS. Th ere are also diff erences 
between the two genotypes in how they modulate macrophage activation 
through their interaction with CD163, and this might lead to diff erent eff ects, 
either plaque stabilization or progression and instability250. Th e Hp (2-2) 
complexes are associated with higher incidence of vascular complications, 
possibly because they induce a stronger infl ammatory signal compared to 
the Hp (1-1) molecules247.
Besides being present on the cell surface, CD163 may be cleaved into a 
soluble form of the receptor, leading to substantial amounts of soluble CD163 
(sCD163) in plasma. Infl ammatory stimuli lead to increased shedding, and 
a role for sCD163 in immune suppression has been proposed. It has been 
suggested that sCD163 in plasma is a novel parameter in diseases aff ecting 
macrophage function and the monocyte/macrophage load in the body.251
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Heme oxygenase 1
Accumulation of iron and heme within the macrophage induces the expression 
of heme oxygenase-1 (HO-1)252, which protects the macrophage against 
oxidative stress and cell death by regulating cellular iron253. Heme oxygenase 
is one of the major mechanisms whereby cells survive oxidative stress254. 
Th ere are three distinct isoforms (HO-1, HO-2, and HO-3), of which HO-2 
and HO-3 are constitutively activated and HO-1 is an inducible isoform255,256. 
CD163-mediated endocytosis of Hp-Hb complexes leads to lysosomal 
degradation of the ligand protein and metabolism of heme by cytosolic heme 
oxygenase. Th e heme molecule is converted by the heme oxygenase into the 
anti-infl ammatory metabolites carbon monoxide (CO), divalent iron (Fe2+), 
and biliverdin, which is subsequently converted to bilirubin.251,257 Free iron is 
capable of participating in deleterious oxidation reactions, but iron released 
from heme also increases the synthesis of ferritin, which has well known 
cytoprotective properties. It has been suggested that the cytoprotective eff ect 
of HO-1 is attributable to a ferritin increment in the cell258. Bilirubin is also a 
potent antioxidant, and it has been shown that higher serum bilirubin levels 
correlate with a lower incidence of myocardial infarction in men259. HO-1 
confers protection against vascular injury via its eff ects on vasoconstriction; 
it has been observed to function as vasodilator, independent of nitric oxide 
(NO) activity260. HO-1-null mice have shown defi cient responses to hypoxia 
with severe right ventricular dilatation, infarcts, and mural clot formation261. 
Th ere is also a report of a HO-1 promoter polymorphism that has relevance 
in coronary artery disease262 and arterial hypertension263 (reviewed by Exner 
and coworkers264). On the other hand, HO-1 can also promote VSMC 
apoptosis265, which may play a critical role in vascular remodeling.
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Figure 7 CD163 and HO-1 signaling in macrophages. Hp-Hb complexes are 
internalized by means of the CD163 scavenger receptor and further 
dismantled within lysosomes. Heme is cleaved by HO-1 into carbon 
monoxide (CO), biliverdin, and free iron, which is subsequently bound to 
ferritin. Extracellular free iron is bound to the transferrin receptor (TfR) and 
transported into the cell, where it is released within endosomes to be bound 
further to ferritin. Abbreviations: HO-1 = heme oxygenase, Hb = hemoglobin, 
Hp = haptoglobin, CO = carbon monoxide, TfR = transferrin receptor.
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AIMS OF THE STUDY
Atherosclerosis is a complex and multifaceted disease, in which several 
processes evolve simultaneously in interaction with systemic changes. It 
is largely an infl ammatory disease15,160 but lipids and their oxidation also 
play a fundamental role123. Th e integrity and physiological functioning of 
the endothelial cell lining are vital107, since plaque rupture and intraplaque 
hemorrhages may take place in advanced plaques, leading to oxidative 
stress and further harmful reactions107,241,242. However, the mechanisms 
leading to the destabilization of plaques remain to be identifi ed. On the 
basis of this background information, to facilitate the risk stratifi cation, a 
series of experiments were designed to elucidate the cellular and molecular 
mechanisms accounting for the destabilization of atherosclerotic carotid 
plaques and the precipitation of symptomatic cerebral ischemia.
Due to the diversity of the disease process, it was considered useful to 
focus on several pathological avenues occurring simultaneously, which 
potentially lead in concert to increased vulnerability of the plaque. Hence, 
this study was initiated as a conventional project driven by the specifi c 
hypotheses described below, but it turned into a data-driven exploration 
of the fi ndings made in a global genomic analysis of the gene expression 
profi les of symptomatic and asymptomatic carotid plaques.
Th e focus was fi rst on determining the role of adhesion molecules as 
essential mediators of infl ammation and recruitment of leukocytes from 
circulation. In the fi rst study, remarkable denudation of the endothelium 
was observed in symptomatic plaques, which led to further examination 
of the factors associating with endothelial detachment. To reveal the 
totally unpredictable processes and gene inductions leading to phenotypic 
divergence into symptomatic and asymptomatic plaque morphologies, a 
DNA microarray study was conducted simultaneously. In these analyses, 
several genes were diff erentially expressed, which led to a further data-driven 
approach to clarify the role of the selected gene products tightly associated 
with the symptomatic phenotype of an atherosclerotic carotid plaque. More 
specifi cally, the experiments aimed to investigate
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i. the expression of cellular adhesion molecules (ICAM-1, VCAM-1, E-
selectin, and P-selectin) on the luminal endothelium and within the 
arterial wall in relation to the symptom status of the carotid plaque (I)
ii. the mechanism leading to endothelial denudation by evaluating the 
expression of apoptotic markers (TUNEL and activated caspase 3) and 
the dominant triggers of cell apoptosis: Fas receptor (FasR) and Fas ligand 
(FasL) (II)
iii. the diff erences in gene expression profi les in bilaterally operated patients 
(one carotid plaque symptomatic and the other asymptomatic in each 
patient) by means of DNA microarray analysis, and by further focusing 
on diff ering profi les regarding genes related to iron/heme metabolism 
(CD163 and HO-1) at both mRNA and protein levels (III)
iv. the role of another diff erentially expressed gene (adipophilin) in the DNA 
microarray study (iii) in the destabilization process. Th is led us to study 
the link between red blood cell extravasation and cholesterol crystal 
formation with the adipophilin-expressing macrophage phenotypes 
populating the symptomatic carotid plaques (IV)
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METHODS
PATIENT SELECTION
Th is thesis is based on the Helsinki Carotid Endarterectomy Study 
(HeCES), launched in 1997. Th e study patients (n=92) were consecutively 
recruited during the years 1997–2000 from patients referred to hospital 
for either an assessment of cerebrovascular symptoms or a suspicion of an 
asymptomatic high-grade carotid artery stenosis based on an ultrasound 
examination. Th e following inclusion criteria were applied: an operable 
asymptomatic or symptomatic 70–99% stenosis of the internal carotid artery 
on digital subtraction angiography (DSA) based on the NASCET criteria266, 
independence in daily life (modifi ed Rankin scale ≤ 2), no history of previous 
ipsilateral carotid endarterectomy or radiotherapy. Patients were excluded 
if they had conditions predisposing to cerebral embolism, such as atrial 
fi brillation, other arrhythmias increasing the risk of cardiac emboli, dilatating 
cardiomyopathy, previous large anterior cardiac infarction, heart failure that 
required therapy, and cardiomegaly in chest X-ray. Each patient’s symptom 
status was based on a clinical examination and a medical history obtained 
by an experienced stroke neurologist. Stroke, transient ischemic attack, 
and amaurosis fugax were regarded as symptoms related to carotid artery 
stenosis. All patients gave written informed consent before enrolling in the 
study. Th e study was approved by the Ethics Committees of the Departments 
of Neurology and Surgery of Helsinki University Central Hospital.
PATIENTS AND SAMPLES
All patients underwent carotid endarterectomy (CEA) in the Department 
of Cardiothoracic Surgery, Helsinki University Central Hospital. Th e 
baseline characteristics are provided in Table 3. Of all patients, 18 were 
completely asymptomatic, and the others had had symptoms either ipsilateral 
or contralateral to the operated plaque. Symptom status was considered 
from the point of view of the operated plaque. Th e patients presenting 
with ipsilateral symptoms underwent CEA 55±46 (mean±SD) days aft er 
symptom onset. Since six patients were operated bilaterally, altogether 98 
CPs were obtained. In order to obtain well-defi ned extreme sets of the 
clinical disease phenotypes, a subgroup of 22 CPs (9 from completely 
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asymptomatic patients without radiological fi ndings and 13 from patients 
with radiologically confi rmed stroke) were analyzed separately in some 
analyses (Figure 8). Th is subgroup is referred to as the “HeCES extremes 
subgroup”. Five additional high-grade carotid specimens were obtained later 
for scanning electron microscopy (SEM) analysis for the verifi cation of the 
ultrastructural appearance of the morphological changes in the endothelial 
cells overlying advanced carotid plaques of similar stage.
Table 3. Baseline characteristics of the study population.
ALL
Symptomatic
CPs
Asymptomatic
CPs P-value
Mean age, y ± SD 65±8 64±8 66±8 NS*
Sex, M/F 61/34 39/15 22/19 NS†
Risk factors (%)
Hypertension 66 65 68 NS†
Diabetes mellitus 24 24 25 NS†
Coronary disease 37 31 44 NS†
Intermittent claudication 30 28 33 NS†
Dyslipidaemic characteristics (%)
     5.0 ≤ Chol (mmol/L) < 6.5 42 23 19 NS†
     Chol ≥ 6.5 mmol/L 21 14 8 NS†
     LDLc ≥ 3.0 mmol/L 54 31 23 NS†
     TG ≥ 2.0 mmol/L 31 15 16 NS†
     HDLc < 1.0 mmol/L 16 8 9 NS†
Cigarette smoking 30 32 27 NS†
Medication (%)
     ASA 66 54 89 0.003†
     Warfarin 28 43 8 0.004†
     Statins    42 41 44 NS†
     ACE inhibitors 21  17 28 NS† 
* Student’s t-test
† Fisher’s exact test
Abbreviations: ASA = acetylsalicylic acid, ACE = angiotensin converting enzyme, Chol = Serum total cholesterol 
consentration, LDLc = LDL cholesterol, TG = triglycerides, HDLc = HDL cholesterol
Th e levels of dyslipidaemic characteristics are determined according to the Health 2000, Health Examination 
Survey in Finland 267.
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Figure 8 Flow chart showing the number of carotid plaques and the number of patients 
in the study. Due to the heterogeneity of the study material, only part of the 
CPs were used in some experiments to obtain well defi ned symptom groups: 
Th e “large extremes”-subgroup includes 44 patients, consisting of all clinically 
asymptomatic patients (n=18) and stroke patients (n=26). Th e “HeCES 
extremes”-subgroup is selected from the “large extremes”-subgroup by taking 
radiology into account. It consisted of all clinically asymptomatic patients 
with completely normal brain imaging (n=9) as well as stroke patients with 
radiologically confi rmed stroke suitable for the symptom (n=13) yielding 
altogether 22 CPs. Th e “bilaterals”-subgroup consisted of the 8 CPs obtained 
from four bilaterally operated patients enabling intraindividual comparison. 
Abbreviations: CP = carotid plaque, CEA = carotid endarterectomy, TIA = 
transient ischemic attack, AF = amaurosis fugax.
ASYMPTOMATIC PLAQUES 
(Contralateral symptom)
25 CPs
TOTALLY ASYMPTOMATIC 
PLAQUES
19 CPs
SYMPTOMATIC PLAQUES
(Ipsilateral symptom)
54 CPs
TIA AND AF
28 CPs
STROKE
26 CPs
”HeCES EXTREMES”
SUBGROUP 22 CPs
all clinically asymptomatic and stroke-patients 
with radiological confirmation of symptom status:
ASYMPTOMATIC PATIENTS (N=9) 
STROKE PATIENTS (N=13)
”LARGE EXTREMES”
SUBGROUP 44 CPs
CPs from all clinically
asymptomatic patients (N=18) 
and all stroke patients (N=26)
98 PLAQUES FROM 92 PATIENTS
(6 bilateral CEAs)
”BILATERALS”
SUBGROUP 8 CPs
4 patients that were operated bilaterally,
yielding 4 comparison pairs, from which
the other CP was asymptomatic and the
other CP was symptomatic
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All CEAs were performed by the same experienced vascular surgeon 
who also performed the transcranial doppler ultrasounds (TCD). Th e 
macroscopic appearance of the fresh endarterectomy specimen was recorded 
by the operating surgeon (ulceration, intraplaque hemorrhage, calcifi cation, 
atheroma). Subsequently, a microscopic evaluation was performed to grade 
each CP according to the AHA classifi cation108. All specimens represented 
complicated class VI lesions. In the CEA technique, the arteriotomy was 
carried out only along the endarterectomy segment to allow removal of the 
tubular specimen, the plaque, as an intact piece. Th ereaft er, the specimen was 
rinsed with saline and cut into 5 longitudinally sectioned slices, one or two of 
which were embedded in Tissue-Tek® O.C.T.™ Compound (Sakura Finetek 
Europe B.V, Zoeterwoude, Netherlands), fresh-frozen in liquid nitrogen, and 
stored at -70°C until sectioned. One slice was fi xed in Carnoy´s fi xative and 
embedded in paraffi  n, and two slices were fresh-frozen for microbiological 
and other purposes, including protein and RNA measurements.
Preoperatively, in addition to a thorough neurological investigation and 
recording of the patient’s medical history, each study patient underwent 
blood sampling and cerebral imaging with MRI or CT and detection of 
microemboli by TCD as follows: Th e ipsilateral middle cerebral artery was 
insonated for one hour with a 2 MHz multidepth transducer (Nicolet-EME 
Pioneer) at two depths (40–60 mm) through a transtemporal window. Th e 
Sound Trak saved the audio data according to the following constant settings: 
sample size 8 mm, FFT (Fast Fourier Transformation) resolution 128 bins, 
FFT overlap 51%, pulse repetition frequency 6.25 kHz, and threshold 6 dB 
(dependent on the manufacturer). Th e criteria used to consider the signal as 
microembolic were short duration (<300 ms), time delay in the appearance 
of the signal at diff erent insonation depths, and characteristic sound.
IMMUNOHISTOCHEMISTRY
Th e primary antibodies used in immunohistochemistry and in double 
labeling are summarized in Table 4. Representative staining patterns for 
some of the used antibodies are shown in Figure 17.
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Table 4. Primary antibodies used in immunohistochemistry and in double labeling 
immunofl uorescence.
Original
publication Antibody
Dilution / incuba-
tion time Manufacturer
I UHP-9 mab mouse anti-human ICAM-1 1:500 / 1 h Made in ascites
I
mab mouse anti-human 
VCAM-1, Clone 1.4C3 1:50 / 1 h
DAKO A/S, Glos-
trup, Denmark
I
mab mouse anti-human CD62P, 
Clone CLB-tromb/6 C2 1:200 / 1 h
Research Diagnos-
tics Inc., Concord 
MA, USA 
I
mab mouse anti-human CD62E, 
Clone 1.2B6 1:50 / 1 h
DAKO A/S, Glos-
trup, Denmark
I
mab mouse anti-human CD31, 
Clone JC/70A 1:50 / 1 h
DAKO A/S, Glos-
trup, Denmark
I
pc goat anti-human VWF, 
FITC-conjugated 1:500 / 1 h
Gift  from Dr. Mari 
Pinola
I
nonsense mab mouse anti-human 
X63 (neg. control) 1:200 / 1 h
American type 
Culture Collection, 
Rockville, MD, USA
I, II
pc rabbit anti-human IgG
(neg. control) 
Equivalent dilutions 
/ 1 h
VECTOR Laborato-
ries, CA, USA
II pc rabbit anti-human FasR 1:400 / 1 h Santa Cruz, CA
II 10) pc rabbit anti-human FasL 1:200 / overnight Santa Cruz, CA
II pc rabbit anti-human Ki-67 1:50 / 1 h Zymed, CA
II
mab rabbit anti-human cleaved 
Caspase-3, Asp175, 5A1 1:150 / overnight
Cell Signaling, Bev-
erly MA
III pc rabbit anti-human HO-1 1:1500 / overnight
Stressgen, Victoria 
BC, Canada
III mab mouse anti-human CD163, clone 10D6 1:100 / 1 h
Novocastra Labora-
tories Ltd., Newcas-
tle, UK
IV mab mouse anti-human adipophilin 1:100 / 1 h
American Research 
Products, Inc., Bel-
mont, MA, USA
IV mab mouse anti-human CD34 1:200 / 1 h
Novocastra Labora-
tories Ltd., Newcas-
tle, UK
IV
mab mouse anti-human IgG1 
(neg. control) 1:200 / 1 h
DAKO A/S, Glos-
trup, Denmark
IV
mab mouse anti-human CD68, 
clone PG-M1 1:200 / 1 h
DAKO A/S, Glos-
trup, Denmark
IV
mab mouse anti-human IgG3 
(neg. control) 1:200 / 1 h
ID Labs inc., Glas-
gow, UK
Abbreviations: pc = polyclonal antibody (ab), mab = monoclonal ab
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Peroxidase stainings (I–IV)
Th e frozen CP specimens were cut into longitudinal sections at 4 μm intervals, 
to make sure that they contained the segment of maximal internal carotid 
artery stenosis. Sections were collected on silane-coated slides, air-dried 
for 30 min, fi xed in acetone (-20°C) for 5 min, and air-dried briefl y. One 
section per each antibody was stained with the peroxidase method. Th e 
sections were washed with PBS between the steps. Th e procedure included 
20-minute incubation in normal serum to block nonspecifi c staining, one-
hour incubation with primary antibody at room temperature in a humid 
chamber, 30-minute incubation with biotinylated secondary antibody 
(DAKO A/S, Glostrup, Denmark), 45-minute incubation with the avidin-
peroxidase complex (ABComplex/HRP, DAKO A/S, Glostrup, Denmark), 
and 20-minute incubation with a peroxidase substrate solution, 3-amino-9-
ethylcarbazole (AEC). Finally, the sections were rinsed with distilled water, 
counterstained with Mayer’s hemalum solution (Merck KgaA, Darmstadt, 
Germany), and mounted with coverslips. Immunoglobulin subtypes of the 
corresponding animal were used in equivalent dilutions as negative controls. 
Ferric iron was detected by Perls’ Prussian blue staining.
Part of the tissue samples were fi xed in Carnoy’s fi xative and embedded in 
paraffi  n. Aft er deparaffi  nization, one section was stained with each antibody 
as described above, with the exception that they were also permeabilized by 
incubation for 20 min in 0.3% Triton-X100/PBS solution, and the primary 
antibody was diluted in 0.3% Triton-X100/1.5% normal serum solution.
Immunoﬂ uorescence double labeling (I)
Th e immunofl uorescence double labeling experiment was run in duplicates. 
Carotid plaque sections were washed with PBS between every step, and the 
steps were as follows: 20 min incubation in 20% normal serum diluted in 
Tris/HCl BSA (3%) to block nonspecifi c staining, one-hour incubation at 
room temperature with the fi rst primary antibody in a humid chamber, 30 
min incubation with biotinylated secondary antibody (Vectastain ABC kit, 
VECTOR Laboratories, CA, USA), 30 min incubation with Rhodamine-
conjugated neutravidin (Molecular Probes, Leiden, Netherlands, 5 μg/mL), 
one-hour incubation at room temperature with FITC-conjugated second 
primary antibody in a humid chamber, aft er which they were mounted 
(Vectashield® mounting medium with DAPI, VECTOR Laboratories) with 
coverslips.
Peroxidase double labeling (IV)
Double labeling stainings with peroxidase chromogens were performed 
essentially similarly to the peroxidase stainings described above, but aft er 
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the application of the fi rst primary antibody, the sections were treated with 
the NovoLink™ polymer detection system (Novocastra Laboratories Ltd., 
Newcastle Upon Tyne, UK) according to the manufacturer’s instructions, 
and the chromogen 3,3’-diaminobenzidine (DAB) was applied aft er washing 
with PBS. For antigen retrieval, the sections were then treated for 4 minutes 
in the microwave oven (750 W) in 1 mM EDTA (pH 8), aft er which the 
second primary antibody was applied. Further detection was carried out 
with Novolink™ followed by DAB+Ni as chromogen. Counterstaining with 
Mayer’s hemalum solution was omitted.
IN SITU CELL DEATH DETECTION BY TUNEL LABELING (II)
To detect DNA strand breaks typical of apoptotic cell death in the original 
publication II, a TUNEL assay (In Situ Cell Death Detection Kit, Fluorescein; 
Roche, Mannheim, Germany) was performed on sections cut from paraffi  n-
embedded tissue blocks, according to the manufacturer’s instructions. Th e 
slides were then covered with DNA counterstain VECTASHIELD® mounting 
medium (Vector) with 4’,6-diamidino-2-phenylindole (DAPI). Rabbit IgG 
(Vector, Burlingame, CA) was used in equivalent dilution as a negative 
control.
MICROSCOPY (I–IV)
Light microscopy (Leitz Laborlux D, Wetzlar, Germany in the original 
publication I, and Axioplan 2, Carl Zeiss, Jena, Germany in original 
publications II-IV) and immunofl uorescence microscopy (Axioplan 
2 and Axiophot 2, Carl Zeiss) were performed by one (II, III) or two (I, 
IV) investigators, who were blinded to the clinical data. In the case of two 
investigators, the eventual scoring value was ascribed as their consensus.
In the original publications I and III, the expression of protein was 
evaluated microscopically, separately in the endothelium and in the intima-
media on a semiquantitative scale. First, the presence of endothelium was 
evaluated as revealed by anti-CD31 staining (an endothelial marker), 
followed by evaluation of the expression of the protein of interest on the 
endothelium from an adjacent section. Th e expression was scored in relation 
to the detected endothelial cell lining. To perform this, scores from 0 to 3 
were ascribed as follows: 0= no staining, 1= fraction of stained endothelium 
less than 1/3 of anti-CD31 staining, 2= stained fraction between 1/3 and 
2/3, and 3= stained fraction 2/3 or more of the CD31-stained endothelium. 
Next, protein expression in the intima-media was also scored from 0 to 3, 
compared to the negative control staining to exclude background staining. 
Th e scoring was: 0= staining pattern similar to negative control, 1= staining in 
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scattered small regions, 2= moderate-sized areas stained, 3= large, confl uent 
areas stained. Th e density of intraplaque microvessels was counted under a 
microscope and expressed as the number of CD-31-immunostained vessels 
divided by the total area of the given CP. Th is was accomplished by using 
an ocular with a quadratic frame with known dimensions (0.98 mm2 for 
the 10x objective).
In the original publication II, the endothelial staining for each antibody 
was quantifi ed in such a way that the number of stained ECs was counted 
and divided by the number of all ECs in that section, as determined from 
an adjacent section stained against the endothelial marker CD31. Hence, 
the fraction (%) of stained ECs was obtained for each plaque. Th e intimal 
staining was analyzed by using the image analysis soft ware from Carl Zeiss 
(KS 300 Imaging System, Release 3.0, Carl Zeiss, Hallbergmoos, Germany), 
in which the whole immunostained area was initially measured, followed 
by measurement of the total section area, and fi nally the fraction (%) of 
immunostained area was calculated by dividing the stained area by the 
total section area. For antibodies that expressed a scarce staining pattern, 
the intimal staining was quantifi ed by counting one by one the number 
of immunostained cells and by dividing the cell count by the whole area 
of the specimen, whereby the relative density of immunostained cells was 
obtained.
In the original publication IV, a method modifi ed from a previous approach 
by Kockx and coworkers 241 was applied to obtain detailed distribution data 
from immunohistochemical stainings. All immunohistochemically stained 
sections were photographed with a digital camera (AxioCam MRc, Axioplan 
2, Carl Zeiss, Germany), using the smallest objective (1.25x). Th e individual 
images were pieced together with the imaging soft ware, and a grid layer was 
positioned onto each image. Th us, for further evaluation, an image of the 
whole specimen compartmentalized by a squared grid, which consisted of 
2x2 mm ROIs (Region Of Interest) was obtained, and the ROIs were further 
evaluated for specifi c morphological parameters (Figure 1 in IV; Fig. 9). 
Immunohistochemically detected expression of adipophilin in each ROI 
was graded semiquantitatively into four groups: 0= no staining in the ROI, 
1= stained area (A) 1/3 or less of the ROI, 2= stained area 1/3<A≤2/3 of 
the ROI, and 3= more than 2/3 of the ROI immunostained for the protein 
of interest. Th e presence of red blood cells and cholesterol crystals was 
evaluated as follows: 0= not present in the ROI and 1= present in the ROI. 
Th e presence of microvessels was evaluated and graded semiquantitatively 
from 0 to 3 (0= no vessels present in the ROI, 1= a few vessels, 2= a moderate 
number of vessels, 3= many vessels).
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Figure 9 Quantifying protein expression using the ROI (Region of Interest) approach.
SCANNING ELECTRON MICROSCOPY (II)
To evaluate the appearance of endothelium in the original publication II, 
scanning electron microscopy (SEM) was performed. Th e specimen was 
pinned on to a plastic dish, cut longitudinally, immersed in 1% glutaraldehyde 
Tyrode’s solution268 for fi xation, and fl ushed with the fi xative solution. Th e 
endothelium was kept moist at all times. Aft er immersion fi xation, the 
specimens were dissected into 5x15 mm pieces suitable for SEM and further 
processed as described previously268. Th e luminal surface of each specimen 
was assessed under a DSM 962 scanning electron microscope (Carl Zeiss, 
Oberkochen, Germany) operating at an acceleration voltage of 10 kV.
RNA EXTRACTION AND QUANTITATIVE REAL-TIME 
RT-PCR (III, IV)
Total cellular RNA was extracted from each CP with Trizol® reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) and purifi ed with the 
RNeasy Total RNA Isolation Kit (Qiagen) according to the manufacturer’s 
recommendations. Quantitative real-time RT-PCR was performed using 
the Assays-on-Demand™ Gene Expression Products and ABI PRISM® 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s recommendations. Relative gene expression 
was determined by the comparative Ct method, normalizing the expression 
to house-keeping genes, either beta-actin or beta-actin and GADPH.
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PROTEIN ISOLATION AND WESTERN BLOT ANALYSIS (III, IV)
Total cellular proteins were isolated from the phenol-chloroform phase 
left  over from the RNA extraction with Trizol® reagent (Invitrogen Life 
Technologies). Protein samples were quantifi ed by the Bradford method, 
and 15 μg of total protein was analyzed on 10% SDS-polyacrylamide gel 
electrophoresis followed by Western blot analysis. Successful transfer of 
proteins onto PVDF membranes was confi rmed using Ponceau S staining 
of the SDS-PAGE. Membranes were blocked in 5% skimmed milk and 0.1% 
Tween-100 in TBS. Adipophilin (American Research Products, Belmont, MA, 
USA) and beta-actin (Sigma-Aldrich, Saint Louis, MO, USA) were detected 
using mouse monoclonal antibodies at working dilutions of 1:500 and 
1:4800, respectively. Peroxidase-conjugated goat anti-mouse IgG (Molecular 
Probes, Eugene, OR, USA) was used as secondary antibody. Protein bands 
were visualized using ECL Plus Western Blotting Detection Reagents and 
Typhoon 9400 Variable Mode Imager (both from Amersham Biosciences, 
Little Chalfont, UK) according to the manufacturer’s recommendations. 
Adipophilin and beta-actin bands were quantifi ed using ImageQuant TL 
1D Gel Analysis v2003.1 soft ware (Amersham Biosciences). Th e relative 
amount of adipophilin protein is given as the volume of the adipophilin 
band divided by the volume of the beta-actin band.
MICROARRAY ANALYSIS (III)
Microarray experiments were performed using Aff ymetrix GeneChip® 
U95Av2 arrays according to the manufacturer’s recommendations and 
the MIAME guidelines269. Detailed descriptions of all data and protocols 
were submitted to a public repository, ArrayExpress (http://www.ebi.
ac.uk/miamexpress/login.htm, the accession number: E-MEXP-268). 
Each RNA sample was hybridized to its own microarray resulting in eight 
arrays from four patients. Hybridization data were analyzed, using the 
BioC 1.8 Release of the Bioconductor packages270. First, signal intensities 
were calculated and hybridization data normalized across arrays using 
Robust Multi-array Average method271. Genes expressed at a reliable level 
and showing diff erential expression were identifi ed by fi ltering, using the 
following criteria: i) the raw signal > 100 in either plaque from three patients, 
and ii) 1.5-fold diff erence in the mean signal between symptomatic and 
asymptomatic plaques. Diff erential expression was tested by paired t-test 
and Benjamin-Hoechberg multiple testing correction was applied to obtain 
the false discovery rates. Hierarchical clustering was performed using the 
GeneSpring v. 7.1 soft ware (Silicon Genetics) and gene-class testing for 
functional pathways and Gene Ontology (GO) categories by using DAVID 
soft ware applying gene enrichment analysis 272.
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STATISTICAL METHODS (I–IV)
Statistical analyses of baseline characteristics were performed using 
parametric (t-test and Pearson correlation; continuous normal variables), 
nonparametric (Kruskall-Wallis and Mann-Whitney U test; non-normal 
variables) or exact (Fisher’s exact test; binary variables) statistical tests. 
Because of the multitude of variables and the relative paucity of samples, 
univariate analyses were used in the original publications I and II, and 
since the data were not normally distributed or parametric, non-parametric 
statistical tests (Mann-Whitney U, Kruskal-Wallis, chi-square test: Linear-by-
Linear Association, Fisher’s exact test) were used to test the signifi cance of the 
observed diff erences between the groups. Spearman’s correlation coeffi  cients 
(rs) and P-values were calculated to test the associations between the observed 
factors. Diff erences were considered signifi cant for P-values below 0.05 and 
highly signifi cant for values below 0.001. Th ese were performed by means 
of SPSS for Windows soft ware (version 10.07, SPSS, Chicago, IL).
To explore the associations between the covariates (cholesterol crystals, 
red blood cells, and ulceration; original publication IV) and the ordinal 
outcome (adipophilin in ROIs), the statistical analysis was performed using 
a fi xed-eff ects proportional odds regression model. Each covariate was 
analyzed univariately (with no other risk factors) and multivariately (plasma 
cholesterol concentration, BMI, age, and gender as covariates). Additionally, 
to take into account the grid-based multiple measurements of adipophilin 
ROI levels in each specimen where the grid of ROIs covered completely 
the area of the specimen, a mixed eff ects proportional odds model was also 
fi tted. All reported signifi cance levels (P-values) for the studied variables 
are from the multivariate model.
Technical details and results of the statistical analysis are presented in 
the supplement, followed by original original publication IV.
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RESULTS
ICAM-1 expression is increased in the intima of 
asymptomatic carotid plaques (I)
In 95 carotid plaques, typical endothelial cell lining could be detected only 
in 51 cases (54%) according to the CD-31-staining. In these 51 CPs were 
endothelium was detected, 27 CPs (53%) were asymptomatic, and 24 CPs 
(47%) were symptomatic. From the other 44 CPs which were devoid of 
endothelium, 14 (32%) CPs were asymptomatic, and 30 (68%) CPs were 
symptomatic. Hence, there were more symptomatic plaques in the non-
endothelial group (P=0.039).
Adhesion molecules were variably expressed on endothelial cells: ICAM-
1 (a representative staining pattern in Figure 17, A-C) and VCAM-1 were 
more abundant than P-selectin and E-selectin, which showed scattered 
expression on the endothelium. Symptomatic and asymptomatic CPs did 
not diff er signifi cantly in their expression of endothelial ICAM-1, VCAM-1, 
P-selectin, or E-selectin (Figure 10), but elevated endothelial expression of 
ICAM-1 associated with higher sCRP values (Figure 3 in I; P=0.006). Th e 
expression of endothelial P-selectin was stronger when the time delay from 
symptom to CEA was shorter (P=0.020). Other adhesion molecules were 
not associated with this delay.
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Figure 10 Endothelial expression of adhesion molecules. Th e expression of VCAM-1 appears to be 
more extensive in symptomatic CPs, but this association is not statistically signifi cant (B). 
ICAM-1 (A), P-selectin (C), and E-selectin (D) are not associated with symptom status. 
Scoring: 0= no adhesion molecule expression, 1= fraction of immunostained endothelium 
less than 1/3 of anti-CD31 staining, 2= stained fraction between 1/3 and 2/3, 3= stained 
fraction 2/3 or more. Please note the corrected bar graphs as compared to the original 
publication I.
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In the intima-media, ICAM-1 and VCAM-1 expressions were mainly seen 
in infl ammatory cells and smooth muscle cells according to the morphological 
criteria (Figure 4 in I). Th e expressions of P-selectin and E-selectin were 
mainly localized on the endothelium of intraplaque microvessels (Figure 4 
in I). In asymptomatic CPs, the expression of ICAM-1 in the intima-media 
was stronger than in symptomatic CPs (P=0.022, Figure 11). Importantly, 
there was more ICAM-1 expression in the intima-media of the CPs where 
endothelium was detected, compared to those where the endothelium was 
completely denuded (P=0.006). When patients with and without ipsilateral 
stroke were compared, ICAM-1 expression in the intima-media was found 
to be stronger in the patients without prior ipsilateral stroke (P=0.017). 
Th ere was a similar trend in the expression of VCAM-1 in the comparison 
of asymptomatic and symptomatic CPs (P=0.053, Figure 11), but VCAM-
1 expression was lower compared to that of ICAM-1. Selectins were not 
associated with symptom status. E-selectin expression, which predominantly 
localized in intraplaque vascular structures, was associated with more severe 
stenoses. Th e mean stenosis was 83 ± 7% (SD) in the CPs where E-selectin 
was expressed, and 76 ± 9% when there was no E-selectin expression detected 
(P<0.001). E-selectin may have been mediated via local shear stress forces 
toward the vessel wall, especially in cases with severe stenosis.
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Figure 11 Adhesion molecule expression in intima-media. ICAM-1 (A) (P=0.022) and VCAM-1 (B) 
expressions are more extensive in asymptomatic than in symptomatic CPs. P-selectin (C) 
and E-selectin (D) showed no association with the CP’s symptom status. Scoring: 0= similar 
adhesion molecule staining pattern with negative control, 1= immunostaining in scattered 
small regions, 2= moderate-sized areas stained, 3= large areas with immunostaining. 
Please note the corrected bar graphs as compared to the original publication I.
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Th e plasma concentration of sICAM-1 for all patients was 284 ± 73 ng/mL 
(mean ± SD), and that of sVCAM-1 400 ± 96 ng/mL. Neither the sICAM-1 
nor the sVCAM-1 concentrations diff ered signifi cantly between the patients 
with symptomatic or asymptomatic CPs. Th e sICAM-1 concentration was 
higher in the patients suff ering from intermittent claudication than in those 
without claudication (333 ± 73 ng/mL, N = 27 vs. 266 ± 62, N = 62, P<0.001). 
sICAM-1 had strong direct correlation with infl ammation-associated factors, 
such as sCRP, blood sedimentation rate (SR), and blood leukocyte counts, 
and both sICAM-1 and sVCAM-1 correlated inversely with plasma LDL 
cholesterol levels (Table 5). sICAM-1 was higher in current smokers (n=22) 
as compared to nonsmokers (patients who had never smoked n=12) (318 ± 
87 ng/mL vs. 249 ± 62, P=0.009). Soluble adhesion molecule expression did 
not associate with the local expression of adhesion molecules.
Table 5. Associations between soluble adhesion molecules, plasma LDL cholesterol, 
and infl ammation-associated parameters.
(Mean ± SD) sICAM-1 sVCAM-1 
LDL-c (3.4 ± 1.0 mmol/L) rs=-0.276, P=0.022* rs=-0.289, P=0.017*
sCRP (7.8 ± 12.1 μg/mL) rs=0.279, P=0.007* NS*
SR (20.4 ± 14.6 mm/h) rs=0.303, P=0.004* NS*
Leuk (6.8 ± 1.7 x 109/L) rs=0.280, P=0.006* NS*
SR = sedimentation rate.
* Spearman’s correlation
LDL-c = LDL cholesterol
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Endothelial apoptosis is decreased in symptomatic 
carotid plaques (II)
Since signifi cant endothelial denudation in symptomatic CPs was observed 
in the previous study (I), the next aim was to visualize the morphology of 
the endothelium and to assess the role of apoptosis in endothelial cell death 
and detachment. Scanning electron microscopy (SEM) analysis confi rmed 
the morphological signs of severe endothelial damage and erosion. Flattened 
giant endothelial cells (EC) were observed, revealing underlying foam cells, 
and occasional gaps indicating that EC detachment also took place (Figure 
1 in II). Th ese morphological signs of EC decay are compatible with the 
previous observations12,112.
Immunohistochemistry showed endothelial cells of symptomatic CPs to 
be abundantly TUNEL-positive, but less activated caspase 3 (ACA3, marker 
for apoptosis) and Ki-67 (marker for cell proliferation) expression was 
observed (a representative staining in Figure 17, D, E). While endothelial 
TUNEL staining showed similar expression in the diff erent symptom 
groups, there was roughly 30% higher ACA3 staining on the endothelium 
of asymptomatic CPs (4.6 ± 0.7%; mean±SE) than on symptomatic CPs (3.3 
± 0.7%, P=0.049; Figure 3 in II; Fig. 12). Ki-67 was equally expressed in both 
symptom groups (1.2 ± 0.3% in SCPs vs. 1.2 ± 0.3% in ACPs; Figure 3 in II; 
Fig. 12). Furthermore, there was a signifi cant positive correlation between 
endothelial ACA3 and Ki-67 expression (rs=0.275, P=0.040).
Markedly elevated endothelial expression of FasR and FasL was observed 
by immunohistochemistry (a representative staining in Figure 17, F, G). 
FasR expression was similar on the endothelium of asymptomatic CPs and 
symptomatic CPs (58.4 ± 4.7% vs. 56.4 ± 4.0%.; Figure 3 in II; Fig. 12). On the 
contrary, FasL expression was markedly more abundant on the endothelium 
of symptomatic CPs (66.4 ± 4.4%) than on asymptomatic CPs (53.9 ± 4.5%, 
P=0.047; Figure 3 in II; Fig. 12). In the intima, there were no diff erences 
in either TUNEL and ACA3 staining or FasR, FasL, and Ki-67 expressions 
between the two symptom groups.
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Figure 12 Endothelial cell (EC) staining for TUNEL, ACA3, Ki-67 (left  hand panel), 
and FasR and FasL (right hand panel) in both asymptomatic (n=41) and 
symptomatic (n=54) human carotid artery plaques (CP). Th e bars represent 
the mean ± SE values of the fraction (%) of immunostained ECs out of all ECs 
counted from the CD31 staining. Th e asterisk indicates a statistical diff erence 
with P<0.05.
Genes involved in iron and heme metabolism 
(CD163 and HO-1) are overexpressed in symptomatic 
carotid plaques (III)
Since it turned out that a mere hypothesis-driven approach did not yield robust 
molecular markers diff erentiating between symptomatic and asymptomatic 
CPs, a DNA microarray analysis was conducted simultaneously with study II, 
to reveal unpredictable processes and gene inductions leading to phenotypic 
divergence into symptomatic and asymptomatic plaque morphology. Th e 
microarray analysis was performed initially for all the patients operated 
bilaterally (n=4), i.e. in whom one CP was symptomatic and the other 
asymptomatic (“Bilaterals”-subgroup, Figure 8) yielding 8 CPs.
In the microarray analysis, 33 genes showed a more than 1.5-fold 
diff erence in mRNA expression between asymptomatic and symptomatic 
CPs in an intraindividual setting (Table 6). Th e diff erentially regulated genes 
showed two main motifs: 1) a large immunoglobulin gene cluster down-
regulated in the symptomatic CPs and 2) a protease gene cluster (cathepsin 
L, MMP 7, 9, and 12) up-regulated in the symptomatic plaques. One of the 
most prominent functional clusters consisted of genes involved in the tissue 
homeostasis of iron and heme, namely HO-1, hemoglobin scavenger receptor 
CD163, hemoglobins beta and gamma, and transferrin receptor (TFRC).
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Table 6. Genes expressed diff erentially in microarray analysis in bilateral cases of carotid artery 
stenosis.
A. Increased expression in symptomatic carotid plaques
Probe Gene name Fold-
Change
P-value† FDR‡
37324_at Transferrin receptor 1.8 0.077 0.283
34210_at CD52 antigen (CAMPATH-1 antigen) 2.1 0.094 0.283
37542_at lipoma HMGIC fusion partner-like 2 1.5 0.100 0.283
41096_at S100 calcium-binding protein A8 
(calgranulin A)
1.9 0.105 0.283
39994_at chemokine (C-C motif) receptor 1 1.7 0.132 0.283
41209_at lipoprotein lipase 1.6 0.154 0.283
32227_at proteoglycan 1, secretory granule 1.7 0.172 0.283
36197_at chitinase 3-like 1 (cartilage glycoprotein-39) 2.2 0.180 0.283
40522_at glutamate-ammonia ligase 
(glutamine synthase) 
1.6 0.206 0.300
31687_f_at, 
32052_at
hemoglobin, beta 1.6 0.210 0.300
34378_at adipose diff erentiation-related protein 1.7 0.228 0.314
668_s_at matrix metallopeptidase 7 
(matrilysin, uterine)
2.7 0.239 0.319
38745_at lipase A, lysosomal acid, cholesterol esterase 
(Wolman disease)
1.5 0.262 0.322
31859_at matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase)
2.0 0.265 0.322
31438_s_at CD163 antigen 1.7 0.266 0.322
32128_at chemokine (C-C motif) ligand 18 
(pulmonary and activation-regulated)
1.6 0.291 0.326
31525_s_at hemoglobin, alpha 1 1.9 0.293 0.326
37603_at interleukin 1 receptor antagonist 2.1 0.294 0.326
33802_at heme oxygenase (decycling) 1 2.6 0.328 0.354
37391_at cathepsin L 1.6 0.338 0.355
1481_at, 
1482_g_at
matrix metallopeptidase 12 
(macrophage elastase)
1.8 0.405 0.405
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B. Decreased expression in symptomatic carotid plaques
Probe Gene name Fold-
Change
P-value† FDR‡
36811_at lysyl oxidase-like 1 -1.5 0.025 0.283
35566_f_at immunoglobulin heavy locus / immunoglobu-
lin heavy constant mu / immunoglobulin 
heavy constant gamma 1 (G1M marker)
-1.8 0.094 0.283
37864_s_at immunoglobulin heavy locus / 
immunoglobulin heavy 
constant gamma 1 (G1M marker) / immu-
noglobulin heavy constant gamma 2 (G2M 
marker) / immunoglobulin heavy constant 
gamma 3 (G3M marker) / immunoglobulin 
heavy constant gamma 4 (G4M marker)
-2.4 0.109 0.283
456_at SWI/SNF-related, matrix-associated, 
actin-dependent 
regulator of chromatin, subfamily d, 
member 3
-1.5 0.115 0.283
41827_f_at Similar to bK246H3.1 (immunoglobulin 
lambda-like polypeptide 1, pre-B-cell specifi c)
-2.4 0.117 0.283
37467_at immunoglobulin heavy constant delta -1.7 0.132 0.283
33273_f_at, 
33274_f_at
immunoglobulin lambda locus / 
immunoglobulin 
lambda constant 1 (MCG marker) / 
immunoglobulin 
lambda variable 3–25 / immunoglobulin 
lambda joining 3 
-2.8 0.136 0.283
35530_f_at immunoglobulin lambda chain variable region 
/ immunoglobulin lambda constant 1 (MCG 
marker) / Immunoglobulin lambda joining 3
-1.7 0.152 0.283
38194_s_at immunoglobulin kappa constant / 
immunoglobulin 
kappa variable 1-5
-2.3 0.161 0.283
33499_s_at, 
33500_i_at, 
33501_r_at
immunoglobulin heavy constant alpha 1 / 
immunoglobulin heavy constant alpha 2 
(A2M marker) / hypothetical 
protein MGC27165
-2.3 0.169 0.283
40161_at cartilage oligomeric matrix protein -2.1 0.169 0.283
34105_f_at, 
41164_at, 
41165_g_at
immunoglobulin heavy locus / 
immunoglobulin 
heavy constant mu
-1.9 0.184 0.283
† Paired t-test, unadjusted P-values. 
‡ FDR= the false discovery rate. P-values adjusted by Benjamin-Hoechberg multiple testing 
correction for the 40 probes tested. If P-values were corrected for all probes on the array (n=12625), 
FDR is 0.98.
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Microarray results were replicated in a larger set of 40 patients (the second 
plaque from each of the four bilaterally operated patients were excluded from 
the “Large extremes”-subgroup yielding 40 independent CPs, Figure 8). In 
the quantitative real-time RT-PCR performed to replicate the microarray 
results, the mRNA expression of both CD163 and HO-1 was signifi cantly 
higher in symptomatic CPs compared to asymptomatic CPs, revealing 1.58-
fold induction for CD163 (95% CI 1.11 to 2.40) and 1.93-fold induction 
for HO-1 (95% CI 1.04 to 3.94) (Figure 1 in III; Fig. 13). CD163 and HO-1 
mRNA expressions directly correlated with each other (rs=0.72, P<0.001). 
TRFC also showed a tendency towards higher expression in symptomatic 
than in asymptomatic CPs, but this was not statistically signifi cant. TRFC 
expression correlated with CD163 (rs=0.62, P<0.001) but not with HO-1 
expression.
In the Western blot experiments (performed to the “HeCES extremes”-
subgroup, 22 independent CPs), the expression of HO-1 protein relative 
to beta-actin was signifi cantly higher in symptomatic than asymptomatic 
CPs (fold change 4.38, 95% CI 1.54 to 12.20) (Figure 2 in III; Fig. 14). HO-
1 protein levels correlated with the HO-1 mRNA levels (rs=0.73, P<0.001, 
Figure 3B in III).
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Figure 13 Gene expression of 
CD163, HO-1, and TRFC 
in asymptomatic and 
symptomatic plaques 
determined by quantitative 
real-time RT-PCR. Bars 
represent mean ± SE. 
Asterisks indicate P<0.05.
Figure 14 Quantifi cation of HO-1 
protein in asymptomatic 
and symptomatic plaques 
by Western blot analysis 
(A). Bars represent mean 
± SE. Asterisks indicate 
P<0.05. A representative 
immunoblot is shown in B.
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In immunohistochemistry, CD163 expression was abundant in the 
shoulder and cap regions of the atheroma (representative staining shown 
in Figure 17, H ; Figure 4 A, D, G and J in III). CD163 antibody stained a 
subpopulation of macrophages, which were either scattered or assembled as 
infi ltrates (Figure 4, D, G and J in III). HO-1 expression was bordering the 
lipid core, mainly in macrophages but also in some vascular smooth muscle 
cells (VSMC) (representative staining shown in Figure 17, I; Figure 4, B, 
E, H and K in III). Th e intensities of HO-1 and CD163 staining correlated 
with each other (rs=0.61, P=0.002) and were also partially colocalized. Both 
CD163 and HO-1 tended to be expressed more intensively in symptomatic 
CPs in correlation with the corresponding mRNA levels (Figure 3 A and B 
in III). HO-1 and CD163 mRNA as well as the HO-1 protein level correlated 
with plaque hemorrhages (CD163 mRNA: rs=0.44, P=0.005, HO-1 mRNA: 
rs=0.54, P<0.001, HO-1 protein: rs=0.52, P=0.016), although asymptomatic 
and symptomatic CPs did not diff er in the frequency of macroscopic 
hemorrhages. 
To reveal prior microhemorrhages, iron deposits were stained. Th ey 
were present in several locations (representative staining shown in Figure 
17, J; Figure 4, C, F, I and L in III), e.g. near the luminal surface, around the 
lipid core, and in the intima-media but, importantly, not systematically at 
the site of a past rupture or erosion. Th e specimens showed no diff erences 
in the amount of iron between symptomatic and asymptomatic plaques. 
Iron deposits correlated signifi cantly with CD163 and HO-1 expression 
both at mRNA (CD163: rs=0.47, P=0.029, HO-1: rs=0.73, P<0.001) and 
protein levels (CD163 immunohistochemistry: rs=0.54, P=0.006, HO-1 
immunohistochemistry: rs=0.54, P=0.02, HO-1 Western blotting: rs=0.71, 
P<0.001).
Adipophilin expression is increased in symptomatic 
carotid plaques, and its expression is associated with the 
presence of red blood cells and cholesterol crystals (IV)
ADFP (the gene for adipophilin) was overexpressed in symptomatic CPs 
in our previous study (III). Th is led us to examine more thoroughly its 
association with the specifi c morphologic parameters of advanced CP and, 
furthermore, its role in the CP destabilization process.
Th e relative expression of ADFP mRNA was higher in stroke-related CPs 
than in asymptomatic CPs, revealing a 1.5-fold induction (1.82 ± 0.19 vs. 
1.25 ± 0.15, P=0.012, Figure 2 in IV; Fig. 15) in the whole material (n=98). 
Th ere was also more ADFP mRNA expression in the CPs that contained 
macroscopic ulceration (P<0.001), and ADFP mRNA expression was also 
associated with the degree of CP stenosis (rs=0.328, P=0.002). It further 
associated with the amount of CD163 mRNA (rs=0.677, P<0.001) and HO-1 
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mRNA (rs=0.751, P<0.001), as assessed previously in the original publication 
III. Men had clearly higher ADFP mRNA expression (P=0.035), as well 
as patients with diabetes (P=0.005) or hypertension (P=0.022) had more 
ADFP mRNA.
Adipophilin protein was quantifi ed in relation to beta-actin by Western 
blot analysis from 22 CPs (the “HeCES extremes”-subgroup, Figure 8). Th e 
expression of adipophilin protein relative to beta-actin was signifi cantly 
higher in symptomatic CPs than asymptomatic CPs (1.04±0.23 vs. 0.46±0.14, 
P=0.043, Figure 2 in IV; Fig. 15 B,C). Adipophilin protein levels correlated 
with the ADFP mRNA levels (rs=0.480, P=0.024). Men had signifi cantly 
more adipophilin (P=0.0003).
Figure 15 Relative ADFP mRNA expression and adipophilin protein levels in 
symptomatic and asymptomatic carotid plaques. Panel A indicates ADFP 
mRNA expression levels in diff erent symptom groups, and panel B shows 
adipophilin protein amount as quantifi ed by Western blot analysis. A 
representative immunoblot of adipophilin is shown in panel C. Bars represent 
mean ± SE and the asterisks indicate P<0.05. TIA = transient ischemic 
attack.
Immunohistochemistry was performed to the whole material. When 
examined morphologically, adipophilin was oft en present near the 
atheromatous or necrotic regions of a plaque (representative staining shown 
in Figure 17, L; Figure 3A in IV), especially around the lipid core, as well 
as in the proximity of extravasated red blood cells (RBC) (representative 
staining shown in Figure 17, K; Figure 3B in IV) and cholesterol crystals 
(Figure 3A and C in IV). Clusters of adipophilin-immunopositive cells were 
also seen within the healthy portions of the vessel wall and underneath 
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the endothelium (Figure 3D in IV), but not particularly in the shoulder 
regions. Double stainings revealed that most of the adipophilin positivity 
localized within macrophages (representative staining shown in Figure 
17, M; Figure 3E and F in IV). Th e ROI analysis based microscopic studies 
of plaque revealed striking colocalizations of adipophilin protein and 
extravasated RBCs (P<0.0001, Figure 4A in IV; Fig. 16 A) and cholesterol 
crystals (P<0.0001, Figure 4B in IV; Fig. 16 B). Adipophilin positivity was 
markedly increased in CPs with macroscopic ulceration compared to CPs 
without ulceration (P<0.0001).
Th e mean adipophilin protein immunopositivity of each CP associated 
directly with the total plasma cholesterol concentration (r=0.222, P=0.045), 
and there was a similar trend for the plasma LDL cholesterol concentration 
(r=0.234, P=0.061). Th e mean adipophilin protein immunopositivity also 
associated with the macrophage count (r=0.379, P=0.001, and with the 
amount of CD163 mRNA (r=0.215, P=0.048) in these CPs, as determined 
previously (III)273. In addition, it correlated positively with the degree of CP 
stenosis (r=0.269, P=0.014) and negatively with the presence of endothelium, 
as found previously (I) (r=-0.306, P=0.005). Men had more adipophilin 
immunoreactivity (P=0.037), and as expected, the mean adipophilin protein 
immunopositivity markedly correlated with ADFP mRNA expression 
(r=0.409, P=0.0002).
Figure 16 Association of adipophilin expression with the presence of cholesterol crystals 
(panel A), and extravasated red blood cells (panel B) in each ROI of an 
individual plaque.
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Figure 17 Representative staining patterns for the antibodies used. Roman numerals 
on the left  indicates the original publication from which the images are 
derived. Panels A-C represent immunofl uorescence double staining with von 
Willenbrand factor (VWF, marker for endothelium; A) and anti-ICAM-1 
(B). Th e overlay image (C) shows the localization of ICAM-1 expression 
in endothelial cells. Th e following panels represent: a marker for apoptosis 
(activated caspase 3, ACA3; D), a marker for cell proliferation (Ki-67; E), 
endothelial FasR (F), endothelial FasL (G), CD163 (H), HO-1 (I), and iron 
deposits (Perls’ Blue; J). Panels K-M represent adipophilin staining. Large 
adipophilin-expressing foam cells can be seen among extravasated red blood 
cells in panel K, the localization of adipophilin around the atheroma and 
cholesterol crystals is shown in panel L, and panel M demonstrates double 
staining with anti-CD68 (macrophage marker; grey color) and anti-
adipophilin antibodies (brown color).
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DISCUSSION
General discussion
As commonly observed, it is not just the degree of carotid stenosis that 
accounts for the onset of symptoms in carotid artery disease. A plaque 
that causes considerable stenosis may remain silent, while another with 
only modest stenosis may cause cerebral symptoms, due to unknown 
reasons so far18. Th e treatment of choice in symptomatic carotid stenosis 
is endarterectomy4. However, not all patients are eligible to surgery, due 
to comorbidity, advanced age, or other reasons, and it would therefore 
be of utmost clinical importance to develop methods that would help to 
diff erentiate between aggressive, symptom-causing carotid plaques and the 
silent ones. Th ese considerations were the major inspiration and motivation 
for launching the present thesis.
Th e following important observations were made: prominent endothelial 
denudation was present in symptomatic plaques, which was not fully 
explained by EC apoptosis, since there was less immunostaining for the 
markers of EC apoptosis, as well as EC proliferation in symptomatic plaques. 
Adhesion molecules (ICAM-1, VCAM-1, P-selectin, and E-selectin) were 
not diff erentially expressed on the endothelium of CPs from diff erent 
symptom groups, but ICAM-1 expression was markedly increased in the 
intima of asymptomatic CPs. Although the immunostaining for markers of 
EC apoptosis was increased in asymptomatic plaques, FasL expression was 
signifi cantly less prominent in these asymptomatic plaques. Furthermore, 
prominent induction of specifi c genes was observed in symptomatic CPs, 
including HO-1, and hemoglobin scavenger receptor CD163. Th e quantity 
of HO-1 and CD163 proteins was also increased in symptomatic CPs, and it 
was associated with intraplaque iron deposits, which did not correlate with 
symptom status itself. ADFP, the gene for adipophilin, was overexpressed 
in symptomatic CPs, and adipophilin protein expression was markedly 
increased in ulcerated CPs, colocalizing with extravasated red blood cells 
and cholesterol crystals.
Atherosclerosis is a multifaceted disease of the arteries, in which several 
complex series of events may co-occur. Atherosclerosis is considered to be 
largely an infl ammatory disease15,160, where lipids and lipoproteins in various 
forms have a crucial role133,135, and immune mechanisms are involved as 
well163,164. Several disease-promoting factors aff ect each other, and it is clear 
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that any study concentrating on only one or a few of them would hardly 
give a satisfactory insight into the whole pathophysiological phenomenon. 
Th us, to gain a better insight, several pathways pertaining to atherosclerosis 
were explored in order to reveal novel cellular and molecular mechanisms 
related to the destabilization of carotid artery plaque.
Th is study was initiated as a traditional hypothesis-driven research project, 
but since it did not lead to rapid identifi cation of novel molecular markers 
of stroke-prone CPs, the simultaneous progress in molecular methodology 
transformed it into a data-driven search for novel pathophysiologic 
mechanisms. Th e study series included both symptomatic and asymptomatic 
clinical patients, who were treated according to the currently valid clinical 
guidelines. Th is resulted in a heterogeneous clinical material, which involved 
many confounding eff ects, e.g. variations in medication, co-morbidity, 
and variable degrees of risk factors – the kind of reality that many clinical 
researchers have to deal with. Yet, the study patients shared one predominant 
feature: they all had a high-grade stenosis in their internal carotid artery, 
which had either caused symptoms or remained silent. Th is dichotomy 
permitted us assume that at least fundamentally diff erent directions of the 
common processes governing the atherosclerotic disease could be identifi ed 
between completely diff erently behaving CPs.
Aft er the onset of symptoms, a CP remains prone to recurrent symptoms 
for months4 and is therefore an interesting source of information regarding 
the molecular factors underlying plaque vulnerability. Hence, it is justifi able 
to study CPs operated some time aft er the onset of symptom despite the 
common concern that the processes (e.g. plaque rupture and subsequent 
wound healing) ongoing in the plaque during the period from the symptom 
onset to surgery might bias the results. In practice, it is impossible to examine 
a symptom-generating plaque just prior to the onset of symptoms. In this 
study, the delay from symptom onset to surgery in the symptomatic patients 
was 55±46 (mean±SD) days. However, half of all symptomatic patients 
with an ipsilateral stenosis were operated within the fi rst 30 days. Th e study 
patients were operated during the years 1997–2000, and it is well known that 
the clinical practice in timing carotid endarterectomy has evolved towards 
shorter delays, which was also true in this material. Th e key parameters of 
the study were analyzed in relation to the time between symptom onset and 
surgery, but no associations could be found, which suggests that the delay 
does not have a major confounding eff ect on the observations.
Th is patient material can be regarded as quite unique, and one might 
expect to obtain information that cannot be attained by other study 
compositions for several reasons: studies have been performed that have 
compared symptomatic and asymptomatic carotid plaques23,174,209,274–283, but 
the number of plaques has oft en been modest, probably due to the clinical 
treatment practice whereby asymptomatic plaques are not oft en operated. 
Furthermore, the diff erences in gene expression between symptomatic and 
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asymptomatic carotid plaques from the same bilaterally operated patients 
have not been studied on a comparative basis before. In these patients, the 
plaques have identical genetic background, and thus the unique environment 
of each plaque must explain the diff erences in the expression profi les, which 
opens completely new possibilities in this line of research.
Atherosclerosis is obviously also a systemic disease. Patients who have an 
atherosclerotic lesion in their carotid artery most probably have atherosclerotic 
lesions in their coronary arteries, peripheral arteries, and renal arteries, all of 
which may lead to serious, life-threatening consequences106,284. Although the 
dynamics of atherosclerotic lesion maturation and clinical behaviour diff er at 
diff erent locations due to diff erences in the size of the artery, hemodynamic 
forces, etc., they most probably share many basic characteristics. Th us, it 
would be of value to shed light on the mechanisms of atherosclerotic carotid 
plaque destabilization that could possibly be applied in the aforementioned 
other serious conditions as well.
Instead of asking what triggers the symptom, we could rephrase the 
question as follows: Why does the lesion remain asymptomatic? Th e stability 
of an atherosclerotic plaque results from active interaction between several 
local and systemic factors. When the balance between the factors maintaining 
plaque stability is disturbed, the lesion insidiously becomes vulnerable to 
rupture, and the symptom may eventually be triggered by rather unrelated 
incidental factors (e.g. systemic infl ammation, infectious disease, and 
physical or hemodynamic stress).
Adhesion molecules in symptomatic carotid disease (I)
Since infl ammation plays an important role in the development of 
atherosclerosis15, the fi rst study (I) of this thesis concentrated on adhesion 
molecules, which are important mediators of infl ammation. Th e expression 
of cellular adhesion molecules is crucial in the infl ammatory component of 
atherosclerosis and contributes to the recruitment of infl ammatory cells to the 
vessel wall (see Figure 5)22,167. Several adhesion molecules have been implicated 
in the initiation and evolution of atherosclerotic lesions22,167,178,183, and circulating 
adhesion molecules have also been suggested to serve as systemic markers of 
the severity of atherosclerotic vascular disease186,188,189,191. However, the present 
results do not confi rm the putative association between increased expression 
of endothelial ICAM-1 and symptomatic carotid artery disease suggested in a 
previous study23. Nor could it be confi rmed that circulating adhesion molecules 
would be useful indicators of symptom status in carotid disease, although they 
correlated with the same risk factors and systemic parameters of infl ammation 
and were more abundant in patients with claudication.
ICAM-1 is known to be constitutively expressed in the non-diseased 
human carotid bifurcations of young people already173. Shear stress regulates 
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the expression of ICAM-1 on the endothelium285. Although the expression 
of endothelial adhesion molecules is a necessary requirement for the 
infi ltration of infl ammatory cells like circulating monocytes within the 
plaque, endothelial ICAM-1 expression may represent an early event in the 
development of an atherosclerotic lesion rather than an event related to plaque 
destabilization. It is possible that, for this reason, the endothelial adhesion 
phenomena seen in this study were no longer decisive in determining the 
symptom status of the CP at the time of the CEA. Th is is supported by the 
observation that the density of macrophages and T lymphocytes did not diff er 
between symptomatic and asymptomatic CPs in this same patient series273. 
Hence, these observations suggest that the above-mentioned morphological 
characteristics of infl ammation – endothelial adhesion molecule expression 
and infl ammatory cell densities – do not diff erentiate between symptomatic 
and asymptomatic CPs at this advanced time point of atherosclerosis.
Previous studies on the association between sCAMs and carotid artery 
disease are numerous but contradictory23,186,188,189,191. It has been suggested 
that there is a chronic fl uctuation of sICAM expression in subjects with 
risk factors for atherosclerosis187. It is probable that the soluble adhesion 
molecules sICAM-1 and sVCAM-1 correlate with systemic markers of 
infl ammation rather than predict the severity of carotid disease.
A novel fi nding in this study was that ICAM-1 expression was more 
pronounced in the intima-media of asymptomatic plaques (a similar trend 
emerged for VCAM-1), suggesting that factors residing in the subendothelial 
layers are important in determining the integrity of the CP and may therefore 
regulate symptom manifestation in carotid artery disease. Th e mechanism 
of this process is unclear but might relate to the vascular smooth muscle cell 
(VSMC) function: VSMCs possess an ability to regress to a less diff erentiated 
phenotype under circumstances of cell culture, injury, and atherogenesis. 
Such phenotypically modulated VSMCs have a decreased volume fraction 
of myofi laments, and they lose their ability to contract, and instead express 
synthetic phenotype, migrate and proliferate readily in response to growth 
factors and cytokines, synthesizing large amounts of matrix proteins117-119. 
Th inning of the fi brous cap has been reported as one feature of unstable 
plaques18. It has been suggested that a lack rather than an excess of smooth 
muscle cells seems to correlate with the thrombotic complications of 
coronary artery disease286. Interestingly, it has been demonstrated in vitro 
that phenotypically modulated VSMCs have increased ICAM-1 expression, 
and that this expression is decreased when the VSMC phenotype reverts 
back to a non-proliferative, contractile form171. It has also been reported that 
ICAM-1 is associated with actin-containing cytoskeleton and α-actinin172, 
which is why ICAM-1 expression may be regulated by the cytoskeletal 
apparatus. Taken together, the increased expression of ICAM-1 in the intima-
media of asymptomatic CPs in this study could be indicative of a proliferative 
VSMC phenotype, which in turn could lead to enhanced plaque integrity 
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by producing extracellular matrix proteins and collagen. Th is is supported 
by the fi nding that ICAM-1 expression was signifi cantly stronger in the 
intima-media of CPs with preserved endothelium.
Th e lack of diff erence in endothelial adhesion molecule expression between 
the symptom categories as well as the previous fi nding of similar amounts of 
infl ammatory cells in both symptom groups273 are consistent with the nature 
of atherosclerosis as an infl ammatory disease, but seem to disprove plaque 
infl ammation as the major cause of symptom generation. Instead, adhesion 
molecules, especially ICAM-1 and VCAM-1, might be markers or play a role 
in the phenotypic conversion of VSMCs and therefore contribute to plaque 
stability. Th e amounts of VSMCs within the diff erent symptom categories 
were similar to those evaluated by α-actin immunohistochemistry273, which 
does not diff erentiate between phenotypes. It could be hypothesized that the 
amounts of diff erent VSMC phenotypes were diff erent in the two symptom 
groups, explaining at least part of the stability of asymptomatic plaques. Th is 
would require further studies.
Endothelial denudation in symptomatic carotid disease, 
and the role of apoptosis (II)
Th e fi rst study (I) showed that symptomatic CPs had signifi cantly more 
endothelial denudation, which could expose subendothelial domains with 
prothrombotic properties. Th is caused us to examine the mechanisms of EC 
detachment. Since apoptosis undoubtedly has a role in atherosclerosis210,2
18,236,287, the second study (II) sought to clarify the role of apoptosis in EC 
denudation in the present patient material. Surprisingly, there was less ACA3 
expression (marker of apoptosis) on the endothelium of symptomatic CPs, 
suggesting that denudation of the endothelial lining occurs via mechanisms 
other than EC apoptosis. Th is interpretation is supported by the following 
considerations: Induction of EC apoptosis may lead to denudation and 
thrombosis13, and turbulent blood fl ow and alterations in shear-stress forces 
can cause EC apoptosis205,210. Yet, ECs disengaged into circulation in disease-
related vascular injury do not necessarily exhibit signs of apoptosis288. In 
vitro studies have also revealed parallel results: Th e morphology of ECs 
may be changed due to mechanical challenges289, which can decrease the 
strength of EC adhesion to the underlying tissue290 owing to impaired cell-
cell contacts291. In addition, turbulent fl uid shear stress promotes vascular 
EC turnover85. Th e other marker for apoptosis, TUNEL, however, did not 
reveal similar fi ndings as ACA3. Th is probably results from the fact that 
TUNEL positivity marks a delayed phase of the apoptotic process within the 
cell287 and may therefore refl ect the distance between the time points they 
represent in the biochemical execution of apoptosis. Furthermore, it has been 
observed that the TUNEL reaction may detect necrotic cells in addition to 
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apoptotic cells292, being thus an unreliable marker for apoptosis.
One possible mechanism of EC denudation could be perturbation of 
cell-cell and cell-matrix adhesion by various proteinases and enzymes. It was 
previously reported, based on this material, that mast cell density was higher 
is symptomatic than asymptomatic CPs273. Mast cells are known to secrete 
proteolytic enzymes, like chymase, capable of degrading the extracellular 
matrix (e.g. fi bronectin), and they can contribute to the loosening of ECs 
from the pericellular matrix293. Also macrophages and derived foam cells 
secrete several matrix metalloproteinases (MMPs) within atherosclerotic 
plaques19,294, and in this material the genes for MMPs 7, 9, and 12 were 
overexpressed in symptomatic plaques (III). Th erefore, the enzymatic activity 
of MMPs can also play an important role in endothelial detachment.
Apoptosis is a physiological phenomenon, which makes it possible to 
maintain a controlled cell population in an organism. Ongoing apoptosis is 
vital in tissue linings, where cells need to be constantly renewed295. In this 
study, the expression intensities of markers of EC apoptosis (ACA3) and 
proliferation (Ki-67) were directly correlated, which result is supported by 
experimental models showing increased cell death and replication in the 
absence of denudation296 . Th e immunostaining intensities of the markers 
for both EC apoptosis and proliferation were decreased in symptomatic CPs, 
indicating a decreased rate of EC turnover in symptomatic carotid artery 
disease compared to asymptomatic disease. Increased EC turnover has been 
reported previously in vascular lesions12, but markers of cellular turnover has 
not been previously studied in advanced carotid plaques relative to symptom 
status. Hence, it can be hypothesized that apoptotic death and renewal of 
vascular ECs may serve as a homeostatic mechanism that protects against 
endothelial injury even during advanced carotid artery disease. Scanning 
electron microscopy demonstrated giant ECs with fl attened morphology. 
Under conditions of constant shear stress and pulsatile stretching, less 
vigorous cell renewal leads to endothelial dysfunction, which may be 
associated with reduced adhesion forces and lead to cell detachment via 
passive mechanisms rather than active execution of cell death programs 
(apoptosis).
One of the main pathways of apoptosis within atherosclerotic lesions is 
the FasR-FasL pathway. Although there was less immunostaining for markers 
of EC apoptosis, the expression of FasL was signifi cantly increased on the 
endothelium of symptomatic CPs. Th is fi nding is in line with the previous 
observations234. Healthy vascular ECs have been observed to actively 
express FasL234 while being resistant to Fas-mediated cell death through 
endogenous mechanisms that block the death-signaling pathway that follows 
the binding of FasR by FasL231,297. It has been proposed that, besides the 
activation of apoptosis, endothelial FasL expression may be a mechanism 
to avoid harmful infl ammation by inducing apoptosis in marginated 
leukocytes seduced by atheroma-derived chemoattractants234. However, in 
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this material, FasL expression was closely associated with symptom status, 
suggesting an association with this deleterious eff ect. It has been observed 
in animal models that FasL expression accelerates atherosclerotic lesion 
formation232, but FasL is also overexpressed in the atherosclerotic plaques 
of humans compared to healthy controls298. Nonetheless, opposite results 
have also been obtained in apolipoprotein E-defi cient mice299, but oft en 
conclusions drawn from animal models to human context are not clear. Th e 
increased FasL expression seen in symptomatic plaques may derive from 
other functions (e.g. signaling) than merely the initiation of the apoptotic 
cascade. In fact, previous studies have indentifi ed a new role for the FasR-
FasL interaction, which positively regulates the CD8+ T cell proliferative 
response by generating a co-stimulatory signal300, an event dictated in part 
by the timing of the up-regulation of FasL expression301. Nevertheless, the 
actual role of FasL in the advanced stage of carotid atherosclerosis remains 
inconclusive and warrants further studies.
To summarize, the endothelial lining was better preserved in asymptomatic 
plaques, which led us to study the integrity of the endothelial lining itself. Th e 
markers of cellular apoptosis as well as cell proliferation were signifi cantly 
more expressed in asymptomatic plaques, suggesting that proper cellular 
turnover is vital for endothelial welfare, which safeguards against the exposure 
of prothrombotic layers and may also promote the stability of the whole 
plaque. Under these circumstances, it seems that endothelial degradation 
is the result of mechanisms other than apoptosis, or may just represent cell 
senescence and other types of passive cell detachment. FasL is a key mediator 
in initiating apoptosis, but there was more FasL expression on the endothelium 
of symptomatic CPs despite the fact that there was less immunostaining for 
the marker of apoptosis. Th is is an apparent contradiction, unless FasL has 
another role than fueling the apoptotic pathway. Perhaps the cells were 
suff ering and did not have enough energy to fully execute apoptosis, which 
led to necrosis in the presence of FasR activation.
Iron and heme metabolism in symptomatic carotid 
disease (III)
In the DNA microarray study, among the other interesting phenomena, 
distinct induction of CD163 and HO-1 took place in symptomatic compared 
to asymptomatic plaques. Both results were replicated by real-time RT-
PCR, and HO-1 protein was quantifi ed by Western blot analysis. According 
to litterature survey, only one research team has previously compared 
asymptomatic and symptomatic atherosclerotic plaques for HO-1 or CD163 
expression274. Th ey found that HO-1 was overexpressed in Helicobacter 
pylori infected asymptomatic carotid plaques, but due to methodological 
diff erences, the outcome of these two studies cannot be directly compared. 
79
HO-1 has been found to be increased in advanced atherosclerotic plaques 
as compared to healthy controls302.
Intuitively, one would expect these results to account for intraplaque 
hemorrhages in symptomatic patients. Although CD163 and HO-1 both 
associated with the presence of iron deposits within the plaque, the iron 
deposits themselves, which indicated intraplaque hemorrhages, did not 
associate with symptom status. Th ese fi ndings are in line with the previous 
pathological studies showing that intraplaque hemorrhages correlate with 
the degree of carotid artery stenosis rather than with symptom-producing 
plaques18. Since symptomatic plaques did not show any more iron deposition 
but showed a higher level of HO-1 expression, it could be hypothesized 
that microhemorrhages and iron induce a stronger activation response 
in symptomatic CPs due to diff erences in the cellular microenvironment 
within the plaque or the genetic background. Indeed, atherosclerosis-
susceptible mouse strains have been reported to show higher induction of 
HO-1 in response to oxidatively modifi ed LDL than atherosclerosis-resistant 
strains303. Th us, while intraplaque hemorrhages probably have a deleterious 
eff ect on plaque stability, the cellular and molecular response of plaques to 
the liberation of erythrocytes and heme is possibly modulated by individual 
environmental and genetic factors that lead to diff erential expression of 
CD163 and HO-1 with regard to the symptom state. Th is might also explain 
why pathological studies on the role of hemorrhages in plaque destabilization 
have remained inconclusive.
Immunohistochemistry showed that the CD163 and HO-1 proteins were 
localized mainly in areas of active infl ammation characterized by various 
infl ammatory cells, foam cells, extracellular lipids, cholesterol crystals 
and red blood cells. CD163 is considered to mark “alternatively activated 
macrophages”, which have a special regulatory role in immune responses161. 
It can be postulated that over-expression of CD163 in symptomatic plaques 
refl ects diff erences in the cellular composition and activation between 
diff erently behaving plaques. Previous studies of macrophage density in 
the present material did not confi rm the presence of increased density 
in symptomatic plaques273. Still, it is possible that overexpression of 
CD163 indicates over-representation of a certain macrophage subtype in 
symptomatic plaques.
Free iron may induce oxidative damage within tissues by catalyzing 
oxidative modifi cations of LDL and the production of ROS242. Within cells, 
iron is cleaved from heme by HO-1 and subsequently bound by ferritin. Not 
only does ferritin sequester iron in a nontoxic form, but levels of iron regulate 
cellular ferritin levels, protecting cells from damage triggered by excess iron. 
When iron levels are low, ferritin synthesis is decreased and conversely, when 
iron levels are high, ferritin synthesis increases304. HO-1 is regarded as an 
anti-atherogenic agent during the early phases of atheroslerosis305,306, but 
HO-1 expression in this material was increased in symptomatic plaques. Both 
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HO-1 and CD163 have characteristics that might turn harmful in advanced 
atheromas: HO-1 is known to prevent the proliferation of VSMCs and ECs 
aft er vascular injury260, which have an undisputable role in sustaining plaque 
integrity and stability. It has also been speculated that, by converting heme 
to free iron, HO-1 might have a deleterious eff ect if not enough ferritin is 
produced to bind the harmful free iron molecules. CD163, again, is linked 
to an increased risk of vascular complications via its diff erent effi  ciencies to 
remove hemoglobin, depending on the haptoglobin genotypes247,250. Here 
it is possible that the induction of HO-1 and CD163 merely refl ects the 
immune activation in response to intraplaque hemorrhages without being 
a destabilizing phenomenon per se.
To summarize, the formation of intraplaque microhemorrhages has 
sometimes been considered one of the triggers of plaque destabilization. 
In the present work, symptomatic plaques did not contain any more iron 
than asymptomatic ones, but the gene expression intensities of HO-1 and 
the hemoglobin scavenger receptor CD163 were markedly induced in 
symptomatic plaques, suggesting a role for microhemorrhages. Th is implies 
that intraplaque hemorrhage might be an important stochastic event causing 
plaque destabilization, but this process is probably strongly modulated by 
individual environmental and genetic factors. Th e oxidative stress caused 
by a hemorrhage could be an important trigger in activating the phenotype 
switch in VSMCs or in activating macrophages.
Lipid load of symptomatic carotid plaques, and the role 
of adipophilin (IV)
Th e presence of lipids has been considered necessary, although not suffi  cient, 
for the development of atherosclerosis123. A necrotid lipid core is the 
hallmark of an advanced atherosclerotic lesion. Th is lipid core results from 
an imbalance between the lipid infl ow mainly in a form of LDL particles and 
the lipid outfl ow facilitated by HDL particles in reverse cholesterol transport 
process135. Lipoproteins are derived directly from blood into the arterial 
intima134 , but intraplaque hemorrhages appear to be a source of cholesterol 
as well136 . Lipids, particularly oxLDL, are toxic to macrophages, which 
eventually results in the death of lipid-laden foam cells, leading to additional 
accumulation of lipid (mainly cholesterol) and thereby contributing to the 
formation of a necrotic lipid core307. In addition, the gene expression data 
from the previous study (III) revealed that the gene for adipophilin was 
overexpressed in symptomatic CPs, and suggested a role for adipophilin 
in lipid accumulation in stroke-prone CPs. Th is observation led to further 
clarifi cation of the role of adipophilin in the destabilization of CPs.
Adipophilin is a lipid droplet protein expressed in several cell types152. It 
has been found to inhibit the lipid effl  ux from macrophages154 and suggested 
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to have a role in the lipid metabolism contributing to the formation of 
a lipid core in human atherosclerotic lesions155. Both ADFP mRNA and 
adipophilin protein were found to be increased in symptomatic compared to 
asymptomatic atherosclerotic carotid plaques. Th ese results are in line with 
the previous studies that have associated adipophilin with atherosclerosis154
,155,308, but this is the fi rst time that adipophilin expression, at either mRNA 
or protein level, has been studied in atherosclerosis in clinical patients with 
regard to their symptom status.
Studies have been performed on perilipin, a lipid droplet protein very 
similar to adipophilin in many respects153,309. Faber and coworkers studied 
ruptured and unruptured human atherosclerotic plaques and found that 
perilipin mRNA and protein are overexpressed in ruptured compared to 
stable plaques310. Th ey suggested that the overexpression of perilipin in 
ruptured plaques might indicate reduced lipolysis of cholesteryl esters in 
those plaques, leading to increased lipid retention and, eventually, plaque 
destabilization. In addition, perilipin ablation by knock-out results in lean 
and obesity-resistant mice311. Due to the similarity between perilipin and 
adipophilin, it is tempting to suggest that adipophilin would have similar 
eff ects, which would agree well with the present fi ndings. It could be 
hypothesized that, by preventing the lipid effl  ux from foam cells, increased 
adipophilin expression contributes to the relentless growth and eventual 
death of these cells and thereby participates in the growth of the confl uent 
necrotic lipid core and the instability of the plaque. Recently, the adipophilin 
gene was inactivated in mice, which resulted in a 60% reduction in hepatic 
triglyceride and resistance to diet-induced fatty liver, but, interestingly, 
no perturbations were observed in gross anatomy and morphology, body 
weight, or the plasma levels of lipids and glucose312.
Interestingly, by means of immunohistochemistry and ROI-based analysis 
of colocalization, adipophilin was found to localize mainly to the areas 
where extravasated RBCs and cholesterol crystals were also found. Since 
erythrocyte membranes contain large quantities of cholesterol in313, and 
since excess cholesterol can create a nidus for nucleation into crystalline 
cholesterol314, this observation is in accordance with the idea that the 
presence of cholesterol crystals refl ects previous intraplaque hemorrhages 
in that area. Th e fi nding that adipophilin expression was strongly increased 
in plaques that also had macroscopic ulceration lends further support to 
the potential destabilizing role of intraplaque hemorrhages. Furthermore, 
the subsequent release of cholesterol from erythrocyte membranes and the 
ensuing oxidative and infl ammatory stress could be important triggers in 
the induction of adipophilin expression within symptomatic CPs. Th ese 
suggestions are in line with previous observations indicating that there is 
more extracellular than intracellular lipid (detected by Oil-Red-O staining) 
in symptomatic CPs (Nuotio, unpublished observation).
82
Future research in the ﬁ eld of carotid atherosclerosis
Where to go from here? With reference to the results on increased ICAM-1 
expression in asymptomatic CPs (I), the role of VSMCs in the destabilization 
of an atherosclerotic plaque should be elucidated by quantifying the 
representation of diff erent VSMC phenotypes within the plaque. In 
this material, several specifi c genes related to VSMCs were shown to be 
overexpressed (CNN1, calponin1) or underexpressed (RGS5, regulator 
of G-protein signalling; MYH10, non-muscle myosin heavy polypeptide 
10) in symptomatic plaques, suggesting that the VSMC and the molecular 
machinery in their phenotypic diff erentiation are centrally activated (Ijäs 
et al., unpublished observation). Th e aforementioned proteins could be 
semiquantifi ed by means of Western blot, and their expression could be 
localized within the carotid plaque by immunohistochemistry to reveal 
their possible role in the destabilization of CPs. It has also been speculated 
previously that there is clonality in VSMCs; monoclonal VSMC patches have 
been found in atherosclerotic lesions120,315, and this fi nding could open up 
new prospects for research on the susceptibility of certain plaques, to show 
diff erent reactions in VSMC proliferation and protein production. 
Th e mechanisms of the apparent endothelial denudation of symptomatic 
plaques need to be further clarifi ed. Th e present work found that this 
denudation is not executed primarily by apoptosis, and other mechanisms 
should therefore be elucidated. Th ere is one major transmembrane molecule 
that mediates the adhesion of endothelial cells to the underlying tissues, 
namely N-cadherin316, and since it has been previously observed that detached 
ECs are not necessarily apoptotic288, this transmembrane adhesion protein 
might be an interesting target to investigate in relation to the potentially 
impaired adhesion of ECs to the substratum.
Th e genes for MMPs 7, 9, and 12 were overexpressed (III), while elastin 
(Ijäs et al., unpublished observation), the major substrate for MMP12, was 
underexpressed in symptomatic plaques, suggesting an important role 
for them in plaque destabilization. MMPs are known to degrade cellular 
adhesion and the extracellular matrix, and the clarifi cation of the role of 
particularly these three MMPs could thus shed more light on the process 
of endothelial denudation. Immunohistochemical staining of MMPs would 
give valuable information of the location of these proteinases, and thus shed 
light on their specifi c role within vulnerable CPs.
CD163 expression associated with the symptomatic carotid disease 
phenotype (III). Further research is warranted to clarify the mechanisms 
accounting for this association. One possible mechanism could be the 
diff erent haptoglobin genotypes that are known to produce proteins with 
diff erent binding affi  nities to the CD163 scavenger receptor and therefore 
possibly mediating a diff erential risk in cardiovascular disease247 ,250. 
Another mechanism may be the binding of free hemoglobin to haptoglobin-
83
related protein (Hpr), which is a protein associated with apolipoprotein 
L-1 containing HDL particles in primates317. Hpr binds hemoglobin as 
effi  ciently as haptoglobin, but does not promote any high-affi  nity binding to 
CD163, which may also have a role in diff erent clinical outcome of CD163 
expression317. Th erefore, haptoglobin genotyping or Hpr measurements 
could be interesting lines of research in the future.
CD163 expression is also considered to mark “alternatively activated” 
macrophages 161. Macrophages are known to have a crucial role in 
atherosclerosis, and they secrete various cytokines that have deleterious 
eff ects123. It would be interesting to evaluate the “degree” of activation of 
macrophages, since their number per se obviously did not associate with 
symptom status in this material273. Th ere are a number of macrophage 
markers that can be used to immunostain macrophages, displaying diff erent 
degrees of specifi city. Double and triple immunostainings using several of 
these markers could give some idea of the diff erent classes of macrophages 
and possibly their state of activation. Functional in vitro studies could shed 
further light on their possible roles in atherosclerotic lesion development.
Adipophilin was clearly associated with ulcerated CPs in this material (IV). 
However, knock-out studies on mice suggest that the inhibition of adipophilin 
is benefi cial, but the eff ect is mainly directed to the lipid metabolism in 
the liver, and there are no other major perturbations, at least in the gross 
morphology312. However, neither the eff ect of adipophilin defi ciency in an 
atherosclerotic environment, nor the function of macrophages was studied. 
Th e present results suggest that inhibition of adipophilin in atherosclerotic 
plaques could be benefi cial. Studies on apoliprotein E and adipophilin double 
knock-out mice could be useful in the further elucidation of the role of 
adipophilin in the progression of atherosclerotic plaques. However, there 
are some limitations in the use of animal models318,319. For instance, animal 
models of atherosclerosis do not exhibit plaque rupture and thrombosis320. 
Th erefore, the extrapolation of the results obtained from animal models is 
not always directly possible in humans. 
Th e DNA microarray analysis was performed on whole plaque specimens, 
which precludes more cell-specifi c evaluation of gene expression. Hence, 
the extension of gene expression studies to a level of one cell type by means 
of, for instance, laser capture microdissection (LCM) would be relevant 
and might enable the detection of smaller fold changes in gene expressions. 
LCM might also allow the diff erentiation between activated macrophages 
and phenotype-switched smooth muscle cells (VSMCs).
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Therapeutic implications and perspectives
Th e results obtained in this study together with the currently available 
knowledge about the pathophysiological mechanisms of atherosclerosis 
provides us visions in developing new treatment strategies. 
Since the present results reveal a role of lipids in plaque destabilization, 
lipid (either in blood or locally within the plaque) targeted therapeutical 
applications would certainly be advantageous. Statins (inhibitors of 3-
hydroxy-3-methylglutaryl coenzyme A reductase, HMG-CoA) are already 
proven to be eff ective in reducing stroke risk59,321. However, statins have 
benefi cial eff ects that are not directly related to their cholesterol lowering 
eff ects322, and in animal models simvastatin have been observed to promote 
plaque stability independently of cholesterol lowering323. Statins have been 
reported to have eff ects other than cholesterol-lowering, e.g. eff ects on the 
endothelial function (NO generation and NO-mediated vascular relaxation), 
the recruitment of monocytes and T cells into the arterial intima, their 
activation and secretion of proinfl ammatory factors, and the proliferation of 
VSMCs322, thus statins can prevent and even reverse ongoing infl ammation 
and tissue damage (reviewed by Stoll and coworkers156).
In the present study, plasma lipid levels did not diff er between symptom 
groups (see Table 3), however, current knowledge indicates that apoB and 
apo-A1 concentrations refl ect more reliably the risk associated with increased 
cholesterol levels and vascular disease57,324. Furthermore, it is nowadays 
considered that simultaneous therapy targeted against LDL-lowering and 
HDL-elevation325 could be more effi  cacious, as well as modifi cation of other 
lipid subfractions as triglycerides326. Th e apoB/apo-A1-ratio is considered 
to be the best means monitoring statin therapy as well as of interpreting 
the information from LDL and HDL in estimating the risk of vascular 
disease324. Th erefore, evaluating the apoB/apo-A1-ratio from atherosclerotic 
patients would off er a tool for optimizing statin and other lipid-lowering 
therapies.
Although this work did not demonstrate diff erential endothelial 
expression of any of the studied adhesion molecules (ICAM-1, VCAM-1, 
P-selectin, E-selectin) in relation to symptom status, it could be benefi cial to 
inhibit the expression of these molecules at some stage of the development of 
atherosclerosis to attenuate the infl ammatory reactions within the plaque327. 
Due to the association of selectins with infl ammation, there have been 
attempts to develop a number a selectin-targeted drugs, but only a few of 
these studies have led to clinical trials (reviewed by Kneuer328). Interestingly, 
Chen and coworkers found that E-selectin mucosal booster tolerization 
signifi cantly decreased infarct size in the brain of rats, and they speculated 
that such immunomodulation targeted to activated blood vessel segments 
may be benefi cial and provide immediate cytoprotection to attenuate damage 
in other tissues and organs as well329.
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Genotyping of several genes could give valuable information for the stroke 
risk stratifi cation, and help in targeting proper therapies to the patients at 
high risk. A large number of common polymorphisms have been identifi ed 
in the genes encoding adhesion molecules, and some of these polymorphisms 
have been associated with a diff erential risk of atherosclerotic vascular 
disease183. Th ere is polymorphism in MMP genes, which has been associated 
with diff erences in the risk of coronary artery disease330. As mentioned 
earlier, also diff erent haptoglobin genotypes possibly mediate a diff erential 
risk in cardiovascular disease247,250.
It has been found previously that MMP12, or macrophage metalloelastase, 
causes accelerated atherosclerosis in transgenic rabbits331, and furthermore, 
selective inhibitors of MMP12 have been developed332, making it already 
a target for therapeutic applications. Further research on the other MMPs 
overexpressed in the symptomatic plaques (MMP 7 and 9) could lead to the 
designing of other inhibitors as well. 
Th ere are contradictory reports relating to the association between 
FasL and the progression of atherosclerosis232,298,299. In this material, FasL 
associated with symptomatic CPs (II), without evidence of increased 
expression of markers of apoptosis in these plaques, implying that FasL may 
have another function than signaling apoptosis. Other groups have also found 
an association between FasL expression and accelerated atherosclerosis232,298. 
FasL has indispensable functions (e.g. FasR-FasL interactions are required 
in CD4+ T-cell mediated cytotoxicity333) that lead to serious infl ammatory 
conditions in FasL-defi cient animals, and total abrogation of FasL is therefore 
not possible. But since FasL gene silencing has been performed successfully 
in human carcinoma by means of siRNA334, a similar attempt could be 
envisaged in the future to silence the FasL gene locally in atherosclerotic 
lesions by means of local application or drug-coated stents, for example. 
Th us, several factors can be identifi ed locally within the CP that associate 
with plaque destabilization. However, the use of this knowledge in clinical 
situations to facilitate risk stratifi cation and to diff erentiate between stable 
and vulnerable unoperated plaques is far more problematic. Th e use of 
these specifi c local factors as markers recognizing CP subtypes requires a 
detection system of some kind. MRI has already been used in characterizing 
athrosclerotic plaque components in humans335,336. Furthermore, it has been 
used to demonstrate infl ammation within atherosclerotic plaques in animal 
models 337,338 and humans by means of ultrasmall superparamagnetic particles 
of iron oxide (USPIO) that are administered intravenously and subsequently 
phagocytosed by activated macrophages339. It would be tempting to use this, 
or other high-resolution imaging methods (PET) to detect specifi c factors 
of interest (e.g. activated macrophages) from unoperated carotid plaques by 
labeling these factors with suitable markers. Similar imaging protocols could 
eventually be validated to help in risk stratifi cation and clinical decision 
making in individuals with equivocal indications for surgical therapy.
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SUMMARY AND CONCLUSIONS
Ischemic stroke is the second leading cause of death in the world and also 
a major health hazard in Finland. A high-grade (>70%) atherosclerotic 
stenosis in the carotid artery that gives rise to thromboembolism is a major 
cause of stroke. However, there is signifi cant diversity in the clinical behavior 
between radiologically similar carotid plaques (CP); some are vulnerable 
to rupture and produce ischemic cerebral symptoms, whereas others are 
stable and remain clinically silent. Th e reason for this is unknown but may 
reside in the micromilieu of the plaque. Th e treatment of choice is carotid 
endarterectomy, if symptomatic stenosis of more than 70% is observed, but 
not all patients are eligible to surgery. Endarterectomy off ers an exceptionally 
good opportunity to investigate microscopically atherosclerotic plaques 
with totally diff erent clinical behaviors. Hence, the aim of this study was 
to elucidate the cellular and molecular mechanisms infl uencing the risk of 
symptom generation in carotid artery disease.
Th e study included 92 patients with an operable asymptomatic or 
symptomatic 70–99% stenosis of the internal carotid artery. All patients 
underwent carotid endarterectomy, and the tissue specimens obtained 
were analyzed by immunohistochemistry, which was the main method 
in the original publications I, II, and IV. Th e other methods used were 
scanning electron microscopy, DNA microarray analysis, real-time RT-
PCR, Western blotting, and topographic colocalization analysis by means 
of immunohistochemistry and computerized image analysis.
Despite the fact that symptomatic CPs more oft en showed extensive 
endothelial denudation, they also exhibited decreased expression of the 
molecular markers of EC apoptosis, which were directly associated with 
those of EC proliferation. Th ese fi ndings suggest that integrity of the 
endothelium is of utmost value to safeguard against symptom generation, 
but apoptosis as the primary mechanism of endothelial denudation was 
not likely in the study material used in this thesis. In addition to exposing 
a prothrombotic surface, endothelial denudation could promote leukocyte 
extravasation and the entrance of lipids into the subendothelial space in 
symptomatic plaques, which may lead to a series of infl ammatory, oxidative, 
and other signaling events that have a harmful infl uence on the plaque and 
may be dominant in the transition from a stable CP to an unstable one. 
FasL immunostaining on the endothelium was signifi cantly increased in 
symptomatic plaques, though there was less immunostaining for markers 
of apoptosis, suggesting an independent detrimental role for FasL in the 
process of CP destabilization.
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Th e expression of endothelial adhesion molecules (ICAM-1, VCAM-1, P-
selectin, and E-selectin) did not diff er between symptomatic and asymptomatic 
patients, disproving the role of proadhesive endothelial transition as a principal 
inducer of destabilization in advanced atherosclerotic CPs. Th is notion is in 
line with the fi nding that the counts of infl ammatory cells (macrophages, T-
lymphocytes, mast cells) did not diff er between symptomatic and asymptomatic 
CPs. However, ICAM-1 expression was signifi cantly increased in the intima of 
asymptomatic patients, which might relate to a characteristic smooth muscle 
cell (VSMC) phenotype with a dominance of a matrix protein synthesizing 
protective VSMC phenotype. Increased intimal ICAM-1 expression may 
promote plaque integrity and cohesion.
CD163 and HO-1 mRNA and proteins were overexpressed in symptomatic 
plaques, and their expressions correlated directly with intraplaque iron 
deposits, which were not, however, associated with symptom status. Since 
CD163 and HO-1 are important in the metabolism of heme and iron, 
it can be hypothesized that intraplaque hemorrhages play a role in the 
destabilization of symptomatic plaques. Th e patients seemed to present with 
diff erential activation responses to hemorrhages or liberated heme, possibly 
depending on the microenvironment and composition of the plaque or the 
subject’s genetic background.
Th e expression of adipophilin, a lipid droplet protein, was signifi cantly 
increased in ulcerated symptomatic CPs and colocalized with extravasated 
red blood cells and cholesterol crystals within the plaque. Th is fi nding further 
underscores the role for intraplaque hemorrhages in plaque destabilization. 
It is known that adipophilin inhibits the lipid effl  ux from cells and might 
thus contribute to the destabilization process by increasing the lipid load 
of the atheroma, foam cell formation, and eventual death of the lipid-laden 
macrophage.
To conclude, this investigation altogether revealed several molecular 
and cell-biological mechanisms that associate with vulnerable lesions, but 
it is equally clear that no single factor can alone be a suffi  cient trigger to 
destabilize the plaque during the advanced stage of atherosclerosis. Additional 
translational research is needed to obtain more specifi c information for 
clinical risk stratifi cation and discrimination between stroke-prone carotid 
plaques and stable ones, as well as for the development of prophylactic and 
therapeutic applications. Further investigation of the molecular markers 
and genes found to be overexpressed in symptom-generating plaques in 
this study can provide a starting point for such research.
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